| May 15, 2013 |
SIMPONI® (Golimumab) Receives FDA Approval For Ulcerative Colitis
|
| May 13, 2013 |
Biosense Webster Reports Compelling Results from Ground-Breaking SMART-AF IDE Study on the Safety and Effectiveness of the THERMOCOOL® SMARTTOUCH™ Catheter
|
| May 13, 2013 |
U.S. FDA Grants Priority Review to Simeprevir (TMC435) for Combination Treatment of Genotype 1 Chronic Hepatitis C
|
| May 3, 2013 |
FDA Grants Premarket Approval (PMA) for the SEDASYS® System for Healthy Patients Undergoing Sedation During Routine Colonoscopy and EGD Procedures
|
| May 2, 2013 |
Janssen and Johnson & Johnson to Provide Webcast Presentation of Simeprevir Phase 3 Clinical Data Presented at The International Liver Congress of the European Association for the Study of the Liver (EASL)
|
| May 1, 2013 |
Daratumumab Receives Breakthrough Therapy Designation in Double Refractory Multiple Myeloma from U.S. Food and Drug Administration
|
| Apr 26, 2013 |
Ethicon Launches Next Generation Energy Device at American Society of Colon and Rectal Surgeons' Annual Meeting
|
| Apr 26, 2013 |
INCIVO® Receives Positive Opinion From The Committee For Medicinal Products For Human Use (CHMP) For Twice Daily Dosing For Treatment Of Genotype-1 Hepatitis C Virus
|
| Apr 25, 2013 |
Johnson & Johnson Announces Dividend Increase of 8.2%
|
| Apr 24, 2013 |
Janssen Submits Marketing Authorisation Application for Simeprevir (TMC435) to the European Medicines Agency for the Treatment of Adult Patients with Chronic Hepatitis C Genotype 1 or Genotype 4
|
| Apr 23, 2013 |
Johnson & Johnson to Host Pharmaceuticals Business Review
|
| Apr 23, 2013 |
Findings from Two Phase 3 Studies of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Genotype 1 Chronic Hepatitis C Patients
|
| Apr 18, 2013 |
Johnson & Johnson Announces Sale of Elan American Depositary Shares to Elan
|
| Apr 16, 2013 |
Johnson & Johnson Reports 2013 First-Quarter Results:
|
| Apr 11, 2013 |
Johnson & Johnson to Webcast Annual Meeting of Shareholders
|
| Apr 8, 2013 |
Ibrutinib Receives Third Oncology Breakthrough Therapy Designation from U.S. Food and Drug Administration
|
| Apr 3, 2013 |
Next-Generation Circulating Tumor Cell Test Demonstrates High Efficiency and Accuracy in New Study
|
| Mar 29, 2013 |
U.S. FDA Approves INVOKANA™ (Canagliflozin) for the Treatment of Adults with Type 2 Diabetes
|
| Mar 28, 2013 |
Janssen Submits New Drug Application to U.S. FDA for Simeprevir (TMC435) for Combination Treatment of Adult Patients with Genotype 1 Chronic Hepatitis C
|
| Mar 25, 2013 |
LifeScan Announces Voluntary Recall of All OneTouch® Verio®IQ Blood Glucose Meters
|
| Mar 19, 2013 |
Johnson & Johnson to Host Analyst Conference Call on First-Quarter Results
|
| Mar 12, 2013 |
Johnson & Johnson Announces Opening of London Innovation Centre
|
| Mar 12, 2013 |
Cordis Acquires Flexible Stenting Solutions, Inc.
|
| Mar 8, 2013 |
Janssen Launches EXPLORER, Global Cardiovascular Research Program, Beginning with Five New Studies in Patients with Unmet Medical Needs
|
| Mar 7, 2013 |
Janssen Submits European Marketing Authorisation Application for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes
|
| Mar 4, 2013 |
FDA Issues Complete Response Letter for XARELTO® (rivaroxaban) for the Reduction of Cardiovascular Events in Patients with Acute Coronary Syndrome
|
| Feb 25, 2013 |
Johnson & Johnson Comments on Venezuelan Currency Devaluation
|
| Feb 22, 2013 |
Janssen Files First Regulatory Application for Simeprevir (TMC435) for the Treatment of Genotype 1 Hepatitis C Patients in Japan
|
| Feb 20, 2013 |
Johnson & Johnson to Participate in 2013 Citi Global Health Care Conference
|
| Feb 12, 2013 |
Ibrutinib Receives Two Oncology Breakthrough Therapy Designations from U.S. Food and Drug Administration
|
| Feb 12, 2013 |
Follow-up Data Show ZYTIGA® Plus Prednisone Continues to Delay Progression of Metastatic Castration-Resistant Prostate Cancer in Patients without Prior Chemotherapy
|
| Feb 6, 2013 |
Johnson & Johnson to Participate in 2013 Leerink Swann Global Health Care Conference
|
| Feb 5, 2013 |
XARELTO® to be Studied with Factor Xa Inhibitor Antidote
|
| Feb 4, 2013 |
Ethicon Receives 510(K) Clearance For Enseal® G2 Articulating
|
| Jan 22, 2013 |
Johnson & Johnson Presents Growth Strategies for Medical Devices & Diagnostics Segment
|
| Jan 22, 2013 |
Johnson & Johnson Reports 2012 Fourth-Quarter and Full-Year Results:
|
| Jan 21, 2013 |
Cordis Corporation Announces Two-Year Results from the STROLL Trial
|
| Jan 18, 2013 |
Biosense Webster Showcases Cutting Edge Innovation at Boston AF 2013
|
| Jan 17, 2013 |
Veridex and LabCorp Agreement Brings CellSearch CTC Test to China
|
| Jan 11, 2013 |
Zytiga® Approved In the EU For Use In The Treatment Of Metastatic Castration-Resistant Prostate Cancer Before Chemotherapy
|
| Jan 10, 2013 |
FDA Advisory Committee Recommends Approval of Canagliflozin for Treatment of Adults with Type 2 Diabetes
|
| Jan 2, 2013 |
Johnson & Johnson Announces Quarterly Dividend for First Quarter 2013
|
| Dec 31, 2012 |
FDA Grants Accelerated Approval for SIRTURO™ (bedaquiline) as Part of Combination Therapy to Treat Adults with Pulmonary Multi-Drug Resistant Tuberculosis
|
| Dec 27, 2012 |
New Category I CPT Codes and Payment Rates for Circulating Tumor Cell Testing Effective January 1
|
| Dec 21, 2012 |
Johnson & Johnson to Host Analyst Meeting to Discuss Fourth-Quarter/Full-Year 2012 Financial Results and Medical Devices and Diagnostics Review
|
| Dec 12, 2012 |
Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes
|
| Dec 12, 2012 |
CellSearch® 'Liquid Biopsy' Approved for Breast Cancer Patients in China
|
| Dec 12, 2012 |
The New England Journal of Medicine Publishes Efficacy Data for ZYTIGA® Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer in Patients Who Have Not Received Chemotherapy
|
| Dec 11, 2012 |
Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
|
| Dec 10, 2012 |
FDA Approves Prescribing Information Update for EDURANT® (rilpivirine) to Include 96-Week Data in HIV-1-Infected Treatment-Naive Adult Patients
|
| Dec 10, 2012 |
U.S. FDA Approves Expanded ZYTIGA® Indication For Treatment Of Metastatic Castration-Resistant Prostate Cancer
|
| Dec 7, 2012 |
FDA Approves EVARREST™ Fibrin Sealant Patch
|
| Dec 6, 2012 |
Janssen Submits Applications Requesting Approval Of Stelara® In U.S. And Europe
|
| Dec 5, 2012 |
New Long-Term Study Suggests Lower Mortality in Alzheimer's Patients Treated with Galantamine Versus Placebo
|
| Nov 30, 2012 |
CEO Alex Gorsky Elected Chairman of Johnson & Johnson; Bill Weldon To Step Down After 41-year Career at Johnson & Johnson
|
| Nov 28, 2012 |
FDA Advisory Committee Recommends Accelerated Approval of Investigational Multi-Drug Resistant Tuberculosis Treatment Bedaquiline
|
| Nov 19, 2012 |
Zytiga® Receives Positive Regulatory Recommendation in the European Union for Treatment of Metastatic Castration-Resistant Prostate Cancer before Chemotherapy
|
| Nov 15, 2012 |
Janssen Research & Development Announces Establishment of Global Cross-Pharmaceutical Clinical Trial Investigator Databank
|
| Nov 12, 2012 |
New Phase 3 Findings Show Stelara® Significantly Reduced Signs And Symptoms Of Active Psoriatic Arthritis
|
| Nov 12, 2012 |
Phase 3 Data Show Intravenous Golimumab Inhibited Radiographic Progression In Patients With Active Rheumatoid Arthritis
|
| Nov 10, 2012 |
Efficacy and Safety Data from Phase 2B Trials of Janssen's Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
|
| Nov 9, 2012 |
Health Care Executive, Scholar and Vice Chancellor from UCLA, Dr. A. Eugene Washington, Appointed to Johnson & Johnson Board of Directors
|
| Nov 9, 2012 |
Phase 3 Results Show Canagliflozin as Add-On Therapy to Metformin and Pioglitazone Significantly Lowers Blood Sugar Levels in Adult Patients with Type 2 Diabetes
|
| Nov 9, 2012 |
FDA Approves New 800mg PREZISTA® (darunavir) Tablet
|
| Nov 8, 2012 |
S.M.A.R.T.® Vascular Stent Systems Receive FDA Approval for Use in SFA
|
| Nov 7, 2012 |
Johnson & Johnson to Participate in Credit Suisse 2012 Healthcare Conference
|
| Nov 2, 2012 |
Janssen and Johnson & Johnson to Provide Webcast Presentation of Immunology Pivotal Phase 3 Data Being Presented at the American College of Rheumatology Annual Meeting
|
| Nov 2, 2012 |
FDA Approves XARELTO® (rivaroxaban) to Treat Deep Vein Thrombosis and Pulmonary Embolism, and to Reduce the Risk of Recurrent Events
|
| Oct 30, 2012 |
Johnson & Johnson Postpones Medical Devices & Diagnostics Review
|
| Oct 25, 2012 |
Johnson & Johnson to Host Medical Devices & Diagnostics Review
|
| Oct 23, 2012 |
SAPPHIRE Worldwide Study Data Presented at TCT 2012
|
| Oct 22, 2012 |
New One-Year Phase 3 Study Results Show Anti-TNF SIMPONI® Maintained Clinical Response In Treatment Of Moderately To Severely Active Ulcerative Colitis
|
| Oct 17, 2012 |
Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2012
|
| Oct 16, 2012 |
Johnson & Johnson Reports 2012 Third-Quarter Results:
|
| Oct 10, 2012 |
Cordis Corporation Announces One-Year Results from the STROLL Trial
|
| Oct 2, 2012 |
First Results from Phase 3 CANVAS Trial Show Canagliflozin as Add-on Therapy to Insulin Lowered Blood Sugar Levels in Patients with Type 2 Diabetes at an Elevated Risk for Cardiovascular Disease
|
| Oct 1, 2012 |
Janssen Announces Worldwide Agreement To Develop And Commercialize JAK Inhibitor For Immunological Diseases
|
| Sep 28, 2012 |
DACOGEN® Approved in the European Union for the Treatment of Acute Myeloid Leukaemia
|
| Sep 28, 2012 |
Subcutaneous Velcade® Approved In The EU For The Treatment Of Multiple Myeloma
|
| Sep 26, 2012 |
Janssen and Johnson & Johnson to Present Latest Phase 3 Results for Canagliflozin in the Treatment of Patients with Type 2 Diabetes
|
| Sep 26, 2012 |
Notice of Postponement of Final Settlement Hearing to October 18, 2012, and Notice of Revised Settlement Objection Deadline of October 5, 2012 for Shareholders Who Received Mailed Notice after September 1, 2012
|
| Sep 25, 2012 |
Janssen Research & Development to Present Latest Phase 3 Results for Canagliflozin in the Treatment of Patients with Type 2 Diabetes
|
| Sep 18, 2012 |
Janssen Submits Application To FDA Requesting Approval Of SIMPONI® Intravenous Formulation For Treatment Of Moderately To Severely Active Rheumatoid Arthritis
|
| Sep 18, 2012 |
Johnson & Johnson Announces Plans to Establish Innovation Centers
|
| Sep 18, 2012 |
Johnson & Johnson to Host Analyst Conference Call on Third-Quarter Results
|
| Sep 13, 2012 |
Sandra E. Peterson to Join Johnson & Johnson as Group Worldwide Chairman and Member of the Executive Committee
|
| Sep 7, 2012 |
Janssen Research & Development Submits Complete Response to the U.S. FDA on XARELTO® (rivaroxaban) for the Reduction of Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome
|
| Sep 5, 2012 |
Johnson & Johnson to Participate in Morgan Stanley Global Health Care Conference
|
| Sep 5, 2012 |
U.S. FDA Grants Priority Review to Bedaquiline (TMC207) for Multi-Drug Resistant Tuberculosis Treatment
|
| Aug 31, 2012 |
Janssen-Cilag International NV (Janssen) Submits European Marketing Authorisation Application for Investigational Multi-Drug Resistant Tuberculosis Treatment Bedaquiline
|
| Aug 30, 2012 |
Janssen Pharmaceuticals, Inc. announces RISPERDAL® consumer protection settlement with 36 states and the District of Columbia
|
| Aug 30, 2012 |
Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab
|
| Aug 29, 2012 |
FDA Approves NUCYNTA® ER (tapentadol) Extended-Release Oral Tablets for the Management of Neuropathic Pain Associated with Diabetic Peripheral Neuropathy
|
| Aug 29, 2012 |
U.S. FDA Grants Priority Review Of ZYTIGA® (Abiraterone Acetate) sDNA For Treatment Of Metastatic Castration-Resistant Prostate Cancer Before Chemotherapy
|
| Aug 23, 2012 |
Janssen Announces Initiation Of Phase 3 Development Program For Sirukumab In Rheumatoid Arthritis
|
| Aug 6, 2012 |
Johnson & Johnson Announces Discontinuation of Phase 3 Development of Bapineuzumab Intravenous (IV) in Mild-to-Moderate Alzheimer's Disease
|
| Jul 19, 2012 |
Notice of Proposed Settlement of Derivative Actions, Final Settlement Hearing, and Right to Appear
|
| |
Stipulation and Agreement of Settlement
Jul 19, 2012
|
| Jul 17, 2012 |
Johnson & Johnson Reports 2012 Second-Quarter Results: Sales of $16.5 Billion decreased 0.7% Versus 2011 Second Quarter; Second-Quarter EPS was $0.50 Excluding Special Items, 2012 Second-Quarter EPS of $1.30 increased 1.6%*
|
| Jul 16, 2012 |
Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2012
|
| Jul 16, 2012 |
Janssen Submits Applications Requesting Approval of Simponi® In U.S. And Europe for Treatment of Moderately to Severely Active Ulcerative Colitis
|
| Jul 10, 2012 |
Janssen Licenses Diabetes Research Programs From Evotec and Harvard University
|
| Jul 9, 2012 |
U.S. FDA Grants Priority Review for XARELTO® (rivaroxaban) Supplemental NDAs for the Treatment of Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), and the Long-Term Prevention of Recurrent DVT and PE
|
| Jul 2, 2012 |
Janssen Research & Development Submits New Drug Application to FDA for Investigational Multi-Drug Resistant Tuberculosis Treatment Bedaquiline (TMC207)
|
| Jun 28, 2012 |
Janssen Acquires Corimmun
|
| Jun 26, 2012 |
Janssen Submits European Marketing Authorisation Application for Canagliflozin in Type 2 Diabetes
|
| Jun 26, 2012 |
VELCADE® Receives Positive Regulatory Recommendation in the European Union for Subcutaneous Administration
|
| Jun 21, 2012 |
FDA Issues Complete Response Letter for XARELTO® (rivaroxaban) for the Reduction of Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome
|
| Jun 18, 2012 |
Johnson & Johnson to Host Analyst Conference Call on Second-Quarter Results
|
| Jun 15, 2012 |
Janssen Submits Additional Marketing Applications for ZYTIGA® in the U.S. and European Union
|
| Jun 14, 2012 |
Johnson & Johnson Announces Completion of Synthes Acquisition
|
| Jun 12, 2012 |
Johnson & Johnson Receives U.S. Regulatory Clearance for Synthes Acquisition; Closing Date for Transaction Set
|
| Jun 10, 2012 |
Positive Results from First Human Clinical Trials of a First-Generation Artificial Pancreas System is Significant Step Forward for Millions with Type 1 Diabetes
|
| Jun 9, 2012 |
Canagliflozin Provided Substantial and Sustained Glycemic Improvements as Monotherapy and in Add-On Combinations in Adults with Type 2 Diabetes in Five Phase 3 Studies
|
| Jun 8, 2012 |
Johnson & Johnson Expects to Incur Special Charge in Second Quarter for Previously Disclosed Legal Matters
|
| Jun 6, 2012 |
New STELARA® Five-Year Data Show Consistent Efficacy and Safety Profile in Treatment of Moderate to Severe Plaque Psoriasis
|
| Jun 5, 2012 |
Janssen and Johnson & Johnson to Present Results from Five Pivotal Phase 3 Studies Evaluating Investigational Canagliflozin for the Treatment of Type 2 Diabetes
|
| Jun 5, 2012 |
New Phase 3 Data Show Stelara® Significantly Reduced Signs and Symptoms of Active Psoriatic Arthritis
|
| Jun 5, 2012 |
New Phase 3 Data Show Simponi® Intravenous Formulation Significantly Improved Rheumatoid Arthritis Signs and Symptoms in Patients with Active Disease
|
| Jun 2, 2012 |
ZYTIGA® Plus Prednisone Show Improvements in Asymptomatic or Mildly Symptomatic Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer
|
| May 31, 2012 |
Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes
|
| May 29, 2012 |
FDA Issues Complete Response Letter for 800mg PREZISTA® (darunavir) Tablet
|
| May 25, 2012 |
Janssen and Johnson & Johnson to Provide Webcast Presentation of ZYTIGA® (abiraterone acetate) Phase 3 Clinical Data Presented at the American Society of Clinical Oncology Annual Meeting
|
| May 23, 2012 |
FDA Advisory Committee Recommends Against Approval of Oral Anticoagulant XARELTO® to Reduce the Risk of Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome
|
| May 21, 2012 |
New Phase 3 Study Results Show Anti-Tnf Simponi® Induced Clinical Response in Adults with Moderately to Severely Active Ulcerative Colitis
|
| May 17, 2012 |
Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN)
|
| May 9, 2012 |
Janssen Research & Development Submits Supplemental New Drug Application to U.S. FDA for XARELTO(R) (rivaroxaban) to Reduce the Risk of Stent Thrombosis in Patients with Acute Coronary Syndrome
|
| May 2, 2012 |
Johnson & Johnson to Participate in 2012 Deutsche Bank Securities, Inc. 37th Annual Health Care Conference
|
| May 2, 2012 |
Johnson & Johnson (China) Investment Ltd. Acquires Guangzhou Bioseal Biotech Co., Ltd.
|
| May 2, 2012 |
Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
|
| Apr 26, 2012 |
Johnson & Johnson Holds 2012 Annual Meeting of Shareholders
|
| Apr 26, 2012 |
Johnson & Johnson Announces Dividend Increase of 7.0%
|
| Apr 19, 2012 |
Johnson & Johnson to Webcast Annual Meeting of Shareholders
|
| Apr 17, 2012 |
Johnson & Johnson Reports 2012 First-Quarter Results:
|
| Apr 10, 2012 |
Johnson & Johnson to Host Analyst Conference Call on First-Quarter Results
|
| Apr 9, 2012 |
Johnson & Johnson Announces Resignation of Sheri S. McCoy
|
| Mar 28, 2012 |
Ortho-Clinical Diagnostics, Inc. Announces Availability of HTLV-I/II Assay
|
| Mar 27, 2012 |
FDA Approves INTELENCE® (etravirine) Tablets for Treatment-Experienced Pediatric Patients with HIV-1, Following Priority Review
|
| Mar 26, 2012 |
XARELTO® (rivaroxaban) Demonstrates Comparable Efficacy to Standard of Care for the Treatment and Secondary Prevention of Venous Blood Clots in Patients with Symptomatic Pulmonary Embolism in Pivotal Phase 3 Study
|
| Mar 19, 2012 |
Johnson & Johnson to Provide Webcast Presentation of XARELTO® (rivaroxaban) Phase 3 Clinical Data Presented at the American College of Cardiology's Annual Scientific Sessions
|
| Mar 8, 2012 |
Study Unblinded: ZYTIGA® (abiraterone acetate) Plus Prednisone for Asymptomatic or Mildly Symptomatic Chemotherapy-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer
|
| Feb 28, 2012 |
Johnson & Johnson to Participate in Cowen and Company 32nd Annual Health Care Conference
|
| Feb 27, 2012 |
U.S. FDA Grants Priority Review for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome
|
| Feb 21, 2012 |
Alex Gorsky to Succeed Bill Weldon as CEO of Johnson & Johnson
|
| Feb 17, 2012 |
McNeil Consumer Healthcare Announces Voluntary Nationwide Recall of Infants' TYLENOL® Oral Suspension, 1 oz. Grape Due to Dosing System Complaints
|
| Feb 9, 2012 |
Johnson & Johnson to Participate in 2012 Leerink Swann Global Health Care Conference
|
| Jan 24, 2012 |
Johnson & Johnson Reports 2011 Fourth-Quarter and Full-Year Results:
|
| Jan 17, 2012 |
Johnson & Johnson to Host Analyst Meeting to Discuss Fourth-Quarter and Full-Year 2011 Financial Results
|
| Jan 3, 2012 |
Johnson & Johnson Announces First-Quarter 2012 Quarterly Dividend
|
| Dec 29, 2011 |
Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome
|
| Dec 8, 2011 |
Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-32765
|
| Nov 28, 2011 |
Johnson & Johnson to Participate in the Piper Jaffray 23rd Annual Health Care Conference
|
| Nov 28, 2011 |
EDURANT® (Rilpivirine) Approved in Europe for Treatment-Naïve Adults with HIV-1 Infection with a Baseline Viral Load ≤ 100,000 HIV-1 RNA Copies/mL
|
| Nov 13, 2011 |
Landmark Study Shows that Adding Rivaroxaban to Standard Antiplatelet Therapy Significantly Reduced Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome
|
| Nov 10, 2011 |
Ethicon Endo-Surgery Receives 510(K) Clearance for New ENSEAL® G2 Curved and Straight Tissue Sealers Line--Broadest Range of Advanced Bipolar Tissue Sealers Available for Open and Minimally Invasive Surgery
|
| Nov 7, 2011 |
New Sirukumab (CNTO 136) Phase 2 Data Show Efficacy of Interleukin-6 Inhibitor Across Multiple Dose Regimens in Treatment of Rheumatoid Arthritis
|
| Nov 5, 2011 |
INCIVO® (Telaprevir) Demonstrates Efficacy and Increased Cure Rates among Cirrhotic Patients with Genotype-1 Chronic HCV Compared to Standard of Care
|
| Nov 5, 2011 |
Tibotec to present final safety and efficacy results from phase 2b PILLAR study of Once-daily TMC435 in late-breaker at AASLD
|
| Nov 4, 2011 |
Ethicon-Endo Surgery Completes Acquisition of SterilMed
|
| Nov 4, 2011 |
FDA Approves XARELTO® (rivaroxaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation
|
| Oct 31, 2011 |
Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain
|
| Oct 21, 2011 |
Johnson & Johnson Announces Fourth-Quarter 2011 Quarterly Dividend
|
| Oct 21, 2011 |
FDA Approves Label Update for PREZISTA® to Include 192-Week Data in HIV-1-Infected Adult Patients Starting Treatment
|
| Oct 18, 2011 |
Johnson & Johnson Reports 2011 Third-Quarter Results
|
| Oct 11, 2011 |
Johnson & Johnson to Host Analyst Conference Call on Third-Quarter Results
|
| Oct 5, 2011 |
Scios Inc. Announces Agreement with Department of Justice Regarding NATRECOR®
|
| Sep 28, 2011 |
McNEIL-PPC, Inc. Acquires Full Ownership of the Johnson & Johnson-Merck Consumer Pharmaceuticals Co. Joint Venture
|
| Sep 28, 2011 |
Ethicon Endo-Surgery to Acquire SterilMed
|
| Sep 23, 2011 |
REMICADE® Receives FDA Approval as First Biologic Treatment for Pediatric Ulcerative Colitis
|
| Sep 23, 2011 |
EDURANT® (rilpivirine) Receives Positive Opinion from the Committee for Medicinal Products for Human Use (CHMP) for Use in Treatment-Naïve Adults with HIV-1
|
| Sep 20, 2011 |
INCIVO® (TELAPREVIR) Approved in Europe Offering Higher Cure Rates for Genotype-1 Chronic Hepatitis C Compared to Standard Treatment
|
| Sep 9, 2011 |
FDA Issues Complete Response Letter to Janssen Biotech, Inc. for SIMPONI® Supplemental Biologics License Application
|
| Sep 8, 2011 |
FDA Advisory Committee Recommends Approval of Oral Anticoagulant Rivaroxaban for the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation
|
| Sep 7, 2011 |
ZYTIGA® Approved in the European Union for Metastatic Castration-Resistant Prostate Cancer
|
| Sep 6, 2011 |
Johnson & Johnson to Participate in Morgan Stanley Global Health Care Conference
|
| Sep 1, 2011 |
Young Patients to Benefit from Health Canada Approval of Remicade®* for Treatment of Pediatric Ulcerative Colitis
|
| Aug 26, 2011 |
NUCYNTA® ER (tapentadol extended-release tablets) Receives FDA Approval for the Management of Moderate to Severe Chronic Pain
|
| Aug 19, 2011 |
DePuy Orthopaedics Receives FDA 510(K) Clearance for TRUMATCH ® Personalized Solutions for TRUMATCH® Personalized Solutions
|
| Jul 28, 2011 |
Mcneil Consumer Healthcare Announces Plans for New Dosing Instructions for TYLENOL® Products
|
| Jul 28, 2011 |
ZYTIGA™* (Abiraterone Acetate) Receives Health Canada Approval for Treatment of Metastatic Prostate Cancer
|
| Jul 22, 2011 |
FDA Issues Complete Response Letter to Janssen Biotech, Inc. for SIMPONI® Supplemental Biologic License Application
|
| Jul 22, 2011 |
INCIVO® Receives Positive Opinion from the Committee for Medicinal Products for Human Use (CHMP) for the Treatment of Genotype-1 Hepatitis C Virus (HCV)
|
| Jul 22, 2011 |
ZYTIGA® Receives Positive Regulatory Recommendation in the European Union for Treatment of Metastatic Castration Resistant Prostate Cancer
|
| Jul 21, 2011 |
FDA Advisory Committee Recommends Approval of REMICADE® for Treatment of Pediatric Ulcerative Colitis
|
| Jul 19, 2011 |
Johnson & Johnson Reports 2011 Second-Quarter Results:
|
| Jul 19, 2011 |
EDURANT™ 96-Week Phase 3 Safety And Efficacy Data Presented At International Aids Society Conference
|
| Jul 18, 2011 |
Johnson & Johnson Announces Third-Quarter 2011 Quarterly Dividend
|
| Jul 17, 2011 |
Cilag GmbH International Completes Acquisition of Over-The-Counter Brands of J B Chemicals & Pharmaceuticals Limited
|
| Jul 15, 2011 |
Janssen Pharmaceuticals, Inc. Announces Definitive Agreement To Divest Ortho Dermatologics Division
|
| Jul 12, 2011 |
Johnson & Johnson to Host Analyst Conference Call on Second-Quarter Results
|
| Jul 7, 2011 |
Janssen Pharmaceutica NV Completes Divestiture of Animal Health Business to Elanco, a Division of Eli Lilly And Company
|
| Jul 1, 2011 |
FDA Approves XARELTO® (rivaroxaban tablets) to Help Prevent Deep Vein Thrombosis in Patients Undergoing Knee or Hip Replacement Surgery
|
| Jun 28, 2011 |
Mcneil Consumer Healthcare Announces Voluntary Recall of One Product Lot of TYLENOL® Extra Strength Caplets 225 Count Distributed In the U.S.
|
| Jun 28, 2011 |
Tibotec Pharmaceuticals Announces Agreement With Gilead Sciences to Develop and Commercialize a New Fixed-Dose Combination Of PREZISTA® and Cobicistat
|
| Jun 17, 2011 |
Ortho-McNeil-Janssen Pharmaceuticals, Inc. Voluntarily Recalls One Lot of RISPERDAL® Tablets and One Lot of Risperidone Tablets
|
| Jun 15, 2011 |
Johnson & Johnson Announces Special Charge Related to Restructuring Plans for Cordis Corporation Subsidiary
|
| Jun 15, 2011 |
Cordis Announces Discontinuation of NEVO™ Sirolimus-Eluting Coronary Stent
|
| Jun 14, 2011 |
Former Chairman and CEO of Aetna Inc., Ronald Williams, Appointed to Johnson & Johnson Board of Directors
|
| Jun 6, 2011 |
DACOGEN® (decitabine) showed an overall survival advantage compared with the accepted standard therapies in older patients with newly diagnosed de novo or secondary acute myeloid leukemia
|
| May 26, 2011 |
Johnson & Johnson Highlights Strategies for Growth Through Differentiated Medicines, Transformational Pipeline and Global Product Launches
|
| May 25, 2011 |
New Four Year STELARA™* Data Show Consistent Safety Profile Over Time in Patients with Moderate to Severe Plaque Psoriasis
|
| May 25, 2011 |
Interleukin-6 Inhibitor Sirukumab (CNTO 136) Phase 2 Data Show Promise in the Treatment of Active Rheumatoid Arthritis
|
| May 23, 2011 |
Cilag GmbH International Announces Definitive Agreements to Acquire the Over-The-Counter Brands of J B Chemicals & Pharmaceuticals Limited
|
| May 20, 2011 |
Cordis Receives FDA Approval for EXOSEAL™ Vascular Closure Device
|
| May 20, 2011 |
FDA Approves EDURANT™ (Rilpivirine) for Use in Treatment-Naïve Adults with HIV-1
|
| May 19, 2011 |
Johnson & Johnson to Host Pharmaceuticals Business Review
|
| May 11, 2011 |
Janssen Identifies Trace Amounts of TBA in 5 Batches of PREZISTA®▼ (darunavir) in the EU and Canada
|
| May 9, 2011 |
New Phase 3 Study Results Show REMICADE® is Effective in the Treatment of Pediatric Patients with Moderate to Severe Ulcerative Colitis
|
| May 9, 2011 |
Phase 2b Data Show Treatment with Stelara® Induced and Maintained Clinical Response in Patients with Moderate to Severe Crohn's Disease
|
| May 4, 2011 |
Johnson & Johnson to Participate in Bank of America Merrill Lynch 2011 Health Care Conference
|
| Apr 28, 2011 |
Johnson & Johnson Holds 2011 Annual Meeting of Shareholders
|
| Apr 28, 2011 |
Johnson & Johnson Announces Dividend Increase of 5.6%
|
| Apr 28, 2011 |
ZYTIGA (Abiraterone Acetate) Receives FDA Approval for Treatment of Metastatic Prostate Cancer After Priority Review
|
| Apr 27, 2011 |
Johnson & Johnson and Synthes Announce Definitive Merger Agreement to Create World's Most Innovative and Comprehensive Orthopaedics Business
|
| Apr 26, 2011 |
Johnson & Johnson to Participate in Deutsche Bank 36th Annual Health Care Conference
|
| Apr 20, 2011 |
Johnson & Johnson to Webcast Annual Meeting of Shareholders
|
| Apr 19, 2011 |
Johnson & Johnson Reports 2011 First-Quarter Results
|
| Apr 15, 2011 |
Johnson & Johnson Provides Additional Information Regarding Amended Agreement With Merck
|
| Apr 15, 2011 |
Merck and Johnson & Johnson Reach Agreement on Distribution Rights for REMICADE® and SIMPONI®
|
| Apr 14, 2011 |
Ortho-McNeil Neurologics Voluntarily Recalls Two Lots of TOPAMAX®
|
| Apr 12, 2011 |
Johnson & Johnson to Host Analyst Conference Call on First-Quarter Results
|
| Apr 11, 2011 |
INVEGA® Approved as Treatment for Schizophrenia in Adolescents
|
| Apr 8, 2011 |
Johnson & Johnson Announces Settlement with U.S. Department of Justice and U.S. Securities and Exchange Commission
|
| Apr 5, 2011 |
In Study of Acutely Ill Patients Rivaroxaban Compares Favorably With Enoxaparin in Preventing Venous Thromboembolism but With an Increased Rate of Bleeding
|
| Mar 29, 2011 |
McNeil Consumer Healthcare Announces Voluntary Recall of Certain OTC Products
|
| Mar 29, 2011 |
Tibotec Advances Global Clinical Research Program For TMC435 in HCV; Will Present Four Abstracts Evaluating Safety and Efficacy at EASL
|
| Mar 21, 2011 |
Cordis Demonstrates Commitment to Advancing Therapies for Below-the-Knee Vascular Disease
|
| Mar 14, 2011 |
Janssen Pharmaceutica NV Receives Offer to Acquire Its Animal Health Business
|
| Mar 10, 2011 |
McNEIL-PPC, Inc. Announces Signing of Consent Decree Covering Manufacturing Facilities in Las Piedras, PR, Fort Washington, PA, and Lancaster, PA
|
| Mar 9, 2011 |
European Commission Approves XEPLION® for Treatment of Schizophrenia
|
| Mar 8, 2011 |
Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs
|
| Feb 23, 2011 |
Court of Appeals Overturns $1.8 Billion Patent Verdict for Centocor Ortho Biotech Inc.
|
| Feb 23, 2011 |
Johnson & Johnson to Participate in 2011 RBC Capital Markets' Health Care Conference
|
| Feb 22, 2011 |
Johnson & Johnson to Participate in 2011 Citi Global Health Care Conference
|
| Feb 22, 2011 |
Johnson & Johnson Completes Tender Offer for Crucell and Declares Offer Unconditional
|
| Feb 18, 2011 |
Tibotec Starts Global Phase 3 Clinical Trials Studying TMC435 In Adults With Chronic Genotype 1 HCV
|
| Feb 17, 2011 |
Minimum Acceptance Condition Satisfied
|
| Feb 14, 2011 |
Depuy Orthopaedics Receives FDA 510(K) Clearance for New Titanium Foam Implants
|
| Feb 14, 2011 |
Depuy Orthopaedics Receives FDA 510(K) Clearance For Reclaim Revision Hip System
|
| Feb 8, 2011 |
Crucell Shareholders Adopt Offer Governance Resolutions and Johnson & Johnson Makes Announcement on U.S. Regulatory Matters
|
| Jan 28, 2011 |
Johnson & Johnson Receives Approval from European Commission
|
| Jan 27, 2011 |
Tibotec Signs Multiple Agreements With Generic Manufacturers to Provide Access to New HIV Treatment
|
| Jan 26, 2011 |
New Study Shows Tapentadol Extended Release (ER) May Significantly Reduce Average Pain Intensity for Diabetic Patients Suffering from Painful Peripheral Neuropathy
|
| Jan 25, 2011 |
Johnson & Johnson Reports 2010 Fourth-Quarter and Full-Year Results
|
| Jan 18, 2011 |
Johnson & Johnson to Host Analyst Meeting to Discuss Fourth-Quarter and Full-Year 2010 Financial Results
|
| Jan 14, 2011 |
Johnson & Johnson Provides Update on McNeil Consumer Healthcare Remediation; Announces Completion of Internal Assessment Phase of Comprehensive Action Plan
|
| Jan 14, 2011 |
McNeil Consumer Healthcare Initiates Voluntary Recall of Certain Over-The-Counter (OTC) Products
|
| Jan 5, 2011 |
New Drug Application Submitted to FDA for Rivaroxaban for Prevention of Stroke in Patients with Atrial Fibrillation
|
| Jan 4, 2011 |
INVEGA® Approved as First and Only Antipsychotic Treatment for Schizoaffective Disorder in the European Union
|
| Jan 3, 2011 |
FDA Approves New Dosage Strength For Intelence®
|
| Dec 29, 2010 |
Centocor Ortho Biotech Inc. Submits Application to FDA Seeking Remicad® Pediatric Ulcerative Colitis Indication
|
| Dec 23, 2010 |
Janssen Inc. Announces New Drug Submission for Abiraterone Acetate for the Treatment of Metastatic Advanced Prostate Cancer
|
| Dec 20, 2010 |
Centocor Ortho Biotech Inc. Announces NDA Submission for Abiraterone Acetate for the Treatment of Metastatic Advanced Prostate Cancer
|
| Dec 17, 2010 |
Janssen Seeks European Marketing Authorization for Investigational Hepatitis C Treatment Telaprevir
|
| Dec 15, 2010 |
Johnson & Johnson Announces Executive Appointments: Alex Gorsky, Vice Chairman, Executive Committee Sheri McCoy, Vice Chairman, Executive Committee
|
| Dec 13, 2010 |
FDA Approves Prezista®/Ritonavir Once-Daily Dosing for HIV-1 Treatment-Experienced Adults With No Darunavir Resistance-Associated Mutations
|
| Dec 9, 2010 |
Mcneil Consumer Healthcare Announces Voluntary Recall of All Lots of Rolaids® Extra Strength Softchews, Rolaids® Extra Strength Plus Gas Softchews, and Rolaids® Multi-Symptom Plus Anti-Gas Softchews Sold in the United States
|
| Dec 8, 2010 |
Johnson & Johnson Launches Recommended Public Offer to Acquire Crucell
|
| Dec 6, 2010 |
VELCADE® (bortezomib) in combination with rituximab improves progression- free survival, response rate and time to next anti-lymphoma treatment in patients with relapsed follicular lymphoma
|
| Dec 6, 2010 |
VELCADE® (bortezomib) administered subcutaneously shows comparable response rates and safety profile compared to intravenous administration in the treatment of relapsed multiple myeloma
|
| Dec 1, 2010 |
Janssen Pharmaceutica N.V. Announces Collaboration to Develop Diagnostic Biosignatures for Pre-Symptomatic Identification of Alzheimer's Disease
|
| Nov 30, 2010 |
Johnson & Johnson and Crucell Progress Update: Expect to Commence Public Offer Prior to 10 December 2010
|
| Nov 30, 2010 |
Cordis Enters Distribution Agreement with Ostial Solutions for the Worldwide Distribution of the OSTIAL PRO Stent Positioning System™
|
| Nov 24, 2010 |
Johnson & Johnson to Participate in the Piper Jaffray 22nd Annual Health Care Conference
|
| Nov 19, 2010 |
Analysis of Longer-Term Clinical Study Suggests Psychiatric Hospitalization Rates Decreased in Adults with Schizophrenia Treated with INVEGA® SUSTENNA®
|
| Nov 18, 2010 |
Ethicon Submits Biologic License Application to the FDA for the Fibrin Pad
|
| Nov 17, 2010 |
Patients with Common Heart Rhythm Disorder Demonstrated Improvements in Symptoms and Quality of Life with Catheter Ablation Compared to Treatment with Drug Therapy
|
| Nov 15, 2010 |
Mcneil Consumer Healthcare Announces Voluntary Recall of All Lots of Rolaids(R) Extra Strength Softchews, Rolaids(R) Extra Strength Plus Gas Softchews, and Rolaids(R) Multi-Symptom Plus Anti-Gas Softchews Sold In the United States
|
| Nov 14, 2010 |
Scios Announces Results of ASCEND Heart Failure Study at the Scientific Sessions of the American Heart Association
|
| Nov 11, 2010 |
Centocor Ortho Biotech Inc. Submits Application to FDA Seeking to Expand SIMPONI® Label to Include Inhibition of Structural Damage in Treatment of Psoriatic Arthritis
|
| Nov 11, 2010 |
SEDASYS® System Appeal Has Been Granted By The FDA
|
| Nov 8, 2010 |
New Magnetic Resonance Imaging (MRI) Data Show Efficacy of SIMPONI® in Treatment of Rheumatoid Arthritis
|
| Nov 4, 2010 |
Johnson & Johnson to Participate in Credit Suisse 19th Annual Health Care Conference
|
| Nov 4, 2010 |
Ethicon Endo-Surgery Urges FDA to Grant SEDASYS® System Appeal
|
| Nov 3, 2010 |
virco®TYPE HIV-1 resistance test achieves CE- Marking approval
|
| Nov 2, 2010 |
Ortho-McNeil-Janssen Pharmaceuticals, Inc. Enters into Agreement for CONCERTA(R) Authorized Generic
|
| Nov 1, 2010 |
Ortho Clinical Diagnostics Receives FDA Clearance for Intact Parathyroid Hormone Assay
|
| Nov 1, 2010 |
Week 24 Interim Results From Phase 2b PILLAR Study to be Presented
as Late-breaker at AASLD
|
| Oct 29, 2010 |
Johnson & Johnson and Crucell Provide Progress Update on Preparations for Public Offer
|
| Oct 29, 2010 |
New Data Analyses on CONCERTA® Pediatric Treatment Include Insight on Handwriting Performance and Attention in ADHD
|
| Oct 19, 2010 |
Johnson & Johnson Reports 2010 Third-Quarter Results:
|
| Oct 18, 2010 |
McNeil Consumer Healthcare Announces Voluntary Recall of One Product Lot of Tylenol® 8 Hour Caplets 50 Count Sold in the United States and Puerto Rico
|
| Oct 11, 2010 |
Johnson & Johnson to Host Analyst Meeting to Discuss Third-Quarter Financial Results and Review Pharmaceutical Business
|
| Oct 11, 2010 |
Abiraterone Acetate Significantly Improved Overall Survival for Patients with Metastatic Advanced Prostate Cancer
|
| Oct 6, 2010 |
Johnson & Johnson and Crucell Reach Agreement on Intended Public Offer of Euro 24.75 per Ordinary Share of Crucell
|
| Oct 4, 2010 |
FDA Issues Complete Response Letter to Johnson & Johnson Pharmaceutical Research & Development Regarding New Drug Application for Tapentadol Extended Release
|
| Oct 4, 2010 |
Ethicon, Inc. Introduces Two Innovative Devices for Minimally Invasive Hernia Repair during American College of Surgeons (ACS) Annual Meeting
|
| Sep 30, 2010 |
Janssen to Assume CAEYLX® Global Marketing Rights from Merck
|
| Sep 27, 2010 |
Johnson & Johnson Completes Acquisition of Micrus Endovascular
|
| Sep 27, 2010 |
CYPHER(R) Sirolimus Drug-Eluting Stent Remains Unsurpassed in Terms of Safety and Efficacy
|
| Sep 27, 2010 |
Acclarent, Inc. Introduces Two New Innovations for Minimally-Invasive Sinus Surgery during AAO - Head and Neck Surgery Conference
|
| Sep 27, 2010 |
Centocor Ortho Biotech Inc. Submits Application to FDA Seeking to Expand Simponi® Label in Treatment of Rheumatoid Arthritis
|
| Sep 27, 2010 |
Phase 3 Study Compares Tapentadol Extended Release Tablets to Placebo in Patients with Chronic Low Back Pain
|
| Sep 22, 2010 |
Economic Model Presented at TCT 2010 Suggests That the Use of CYPHER Drug Eluting Stent May Result in Substantial Cost Savings When Compared to Other Drug Eluting Stents
|
| Sep 20, 2010 |
Data from Landmark Study Evaluating Gender Differences In Response To An HIV Therapy Published In Annals Of Internal Medicine
|
| Sep 17, 2010 |
Johnson & Johnson and Crucell In Advanced Negotiations for an All Cash Public Offer of Euro 24.75 Per Ordinary Share of Crucell
|
| Sep 16, 2010 |
Colleen Goggins, Worldwide Chairman, Consumer Group Plans Retirement From Johnson & Johnson in Early 2011
|
| Sep 9, 2010 |
Study of Investigational Agent Abiraterone Acetate for Metastatic Advanced Prostate Cancer Unblinded After Meeting Pre-Determined Criteria
|
| Sep 3, 2010 |
Tibotec Pharmaceuticals Seeks European Marketing Authorization for Investigational Once-Daily HIV Treatment TMC278
|
| Sep 2, 2010 |
Long Term Data Presented at ESC 2010 Shed Further Light on the Benefit of the CYPHER(R) Sirolimus Drug-Eluting Stent Compared to the ENDEAVOR(R) Zotarolimus-Eluting Stent in Important High-Risk Subgroups
|
| Aug 31, 2010 |
Rivaroxaban Successfully Demonstrated Non-Inferiority Compared to Standard of Care for the Prevention of Recurrent Venous Thromboembolism in Pivotal Phase 3 Study
|
| Aug 31, 2010 |
CORDIS announces results of ten-year CYPHER® Sirolimus-eluting coronary stent follow-up
|
| Aug 30, 2010 |
Pivotal Phase 3 Study Compares Tapentadol Extended Release Tablets to Placebo in Patients with Chronic Osteoarthritis Knee Pain
|
| Aug 26, 2010 |
DePuy Orthopaedics Voluntarily Recalls ASR(TM) Hip System
|
| Aug 9, 2010 |
STELARA®Three-Year Efficacy and Safety Data Presented on Patients with Moderate to Severe Plaque Psoriasis
|
| Jul 26, 2010 |
Tibotec Pharmaceuticals Submits New Drug Application for Investigational Once-Daily HIV Treatment TMC278 to U.S. Food and Drug Administration
|
| Jul 22, 2010 |
TMC278 Pivotal Phase 3 Clinical Trials Achieve Primary Objective
|
| Jul 20, 2010 |
Johnson & Johnson Reports 2010 Second-Quarter Results:
|
| Jul 19, 2010 |
Former McKinsey & Company Chairman and Managing Director Ian Davis Appointed to Johnson & Johnson Board of Directors
|
| Jul 19, 2010 |
Phase 3 Open-Label Study Comparing Tapentadol Extended Release Tablets to Oxycodone Controlled Release Tablets Published by Pain Practice
|
| Jul 13, 2010 |
Johnson & Johnson to Host Analyst Conference Call on Second-Quarter Results
|
| Jul 12, 2010 |
Johnson & Johnson Announces Definitive Agreement to Acquire Micrus Endovascular
|
| Jul 12, 2010 |
Ethicon Endo-Surgery Completes Divestiture of Breast Care Business
to Devicor Medical Products
|
| Jul 8, 2010 |
McNeil Consumer Healthcare Announces Voluntary Recall of Certain Over-The-Counter (OTC) Products in the United States, Fiji, Guatemala, Dominican Republic, Puerto Rico, Trinidad & Tobago, and Jamaica
|
| Jun 28, 2010 |
Ortho-McNeil-Janssen Pharmaceuticals, Inc. Announces Oncology Research Collaboration Agreement with the Koch Institute for Integrative Cancer Research at MIT
|
| Jun 26, 2010 |
Johnson & Johnson Pharmaceutical Research & Development Reports Phase 2b Clinical Trial Results Evaluating Canagliflozin to Treat Type 2 Diabetes
|
| Jun 24, 2010 |
McNeil Consumer Healthcare
|
| Jun 23, 2010 |
Biosense Webster Receives FDA Clearances for the CARTOXPRESS(TM) Software Module and LASSO(R) NAV Catheter for its CARTO(R) XP System
|
| Jun 22, 2010 |
Ortho-McNeil-Janssen Pharmaceuticals, Inc. Enters Agreement to Develop and Commercialize Antigen-Based Therapy for Type 1 Diabetes
|
| Jun 21, 2010 |
Ethicon Endo-Surgery Introduces HARMONIC ACE®45 cm Curved Shears At ASMBS
|
| Jun 17, 2010 |
VISTAKON(R) Launches 1-DAY ACUVUE(R) TruEye(TM) Brand Contact Lenses
|
| Jun 16, 2010 |
EMEA Approves Update to Velcade® (bortezomib) Label to Include Survival Benefit in Previously Untreated Patients with Multiple Myeloma
|
| Jun 15, 2010 |
McNeil Consumer Healthcare Recalls Four Product Lots Of Benadryl® Allergy Ultratab™ Tablets, 100 Count, and One Product Lot of Extra Strength Tylenol® Rapid Release Gels, 50 Count
|
| Jun 7, 2010 |
Janssen Pharmaceutica N.V. Announces Expansion of Licensing Agreement for Tapentadol (NUCYNTA® /PALEXIA® /PALEXIS®)
|
| Jun 3, 2010 |
Johnson & Johnson Highlights Growth Strategies for its World-Leading Medical Devices & Diagnostics Segment
|
| Jun 1, 2010 |
Centocor Ortho Biotech Inc. Acquires RespiVert LTD., Strengthens Pulmonary Focus
|
| May 25, 2010 |
Johnson & Johnson to Host Medical Devices & Diagnostics Business Review
|
| May 25, 2010 |
NEVO(TM) Sirolimus-eluting Coronary Stent Continues to Demonstrate Excellent Safety and Efficacy Outcomes in New Twelve-Month Data
|
| May 24, 2010 |
New Data on Invega® Sustenna® and Risperdal® Consta® For Schizophrenia
|
| May 20, 2010 |
Johnson & Johnson to Participate in 2010 Citi Investment Research Global Health Care Conference
|
| May 20, 2010 |
Depuy Mitek To Launch Bristow-Latarjet Instability Shoulder System For Treatment Of Recurrent Joint Instability
|
| May 13, 2010 |
Biosense Webster Introduces the THERMOCOOL® SF Irrigated Catheter in the European Union
|
| May 11, 2010 |
Ethicon Endo-Surgery Introduces Harmonic Focus® Long Curved Shears For Deep Surgical Access
|
| May 7, 2010 |
Data Comparing Nucynta® (Tapentadol) Tablets To Oxycodone Immediate Release Tablets Presented At 2010 American Pain Society Annual Meeting
|
| May 4, 2010 |
McNeil Consumer Healthcare Statement Regarding FDA Inspection Report
|
| May 4, 2010 |
Johnson & Johnson to Participate in Bank of America Merrill Lynch 2010 Health Care Conference
|
| May 3, 2010 |
Ethicon Endo-Surgery SEDASYS® System Receives Regulatory Approval in Canada and CE Mark in European Union
|
| May 3, 2010 |
TAPENTADOL DATA TO BE PRESENTED AT 2010 AMERICAN PAIN SOCIETY ANNUAL MEETING
|
| Apr 30, 2010 |
McNeil Consumer Healthcare Announces Voluntary Recall of Certain OTC Infants' and Children's Products
|
| Apr 29, 2010 |
Ortho-McNeil-Janssen Pharmaceuticals, Inc. Resolves Investigation of Past TOPAMAX® Marketing and Promotional Activities
|
| Apr 27, 2010 |
Johnson & Johnson to Participate in Deutsche Bank 35th Annual Health Care Conference
|
| Apr 27, 2010 |
ASP Sterrad Technology Approved By AFSSAPS for Total Inactivation of Prions
|
| Apr 26, 2010 |
CONCERTA(R) Patent Appeal Denied
|
| Apr 22, 2010 |
Johnson & Johnson Announces Dividend Increase of 10.2%
|
| Apr 20, 2010 |
Johnson & Johnson Reports 2010 First-Quarter Results:
|
| Apr 15, 2010 |
Johnson & Johnson to Webcast Annual Meeting of Shareholders
|
| Apr 15, 2010 |
Remicade® Study Results Show Greater Steroid-Free Remission and Mucosal Healing Compared With Conventional Immunomodulator Azathioprine in Treatment of Crohn's Disease
|
| Apr 14, 2010 |
New Study on Continuity of Care for Patients with Schizophrenia and Schizoaffective Disorder Presented at 2010 Quality of Behavioral Health Care Conference
|
| Apr 13, 2010 |
FDA Approves New Drug Application for PANCREAZE(TM)
|
| Apr 13, 2010 |
Johnson & Johnson to Host Analyst Conference Call on First-Quarter Results
|
| Apr 9, 2010 |
First Patients Enrolled in Cordis Trial of New Stent Graft System to Treat Abdominal Aortic Aneurysm
|
| Mar 30, 2010 |
Ethicon Endo-Surgery Announces Receipt of Offer to Purchase Breast Care Business
|
| Mar 15, 2010 |
Positive Long Term Data Presented At ACC 2010 Demonstrate Sustained Safety and Efficacy Advantages of the Cypher® Sirolimus Drug-Eluting Stent Over the Endeavor® Zotarolimus-Eluting Stent
|
| Mar 11, 2010 |
Cordis Unveils Next Generation CoCr Coronary Stent
|
| Mar 5, 2010 |
Johnson & Johnson Consumer Companies, Inc., Unveils CYTOMIMIC(TM) Technology at 68th Annual Meeting of the American Academy of Dermatology
|
| Mar 4, 2010 |
STELARATM and REMICADE® Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting
|
| Mar 2, 2010 |
Johnson & Johnson to Participate in the 30th Annual Cowen and Company Health Care Conference
|
| Feb 24, 2010 |
New Guidelines Recommend DORIBAX® For Initial Treatment Of Complicated Intra-Abdominal Infections In Adults
|
| Feb 24, 2010 |
LifeScan Recalls Specific Lots of Consumer and Professional OneTouch® SureStep® Test Strips Due To Inaccurate Readings at High Levels
|
| Feb 23, 2010 |
Johnson & Johnson to Participate in RBC Capital Markets' Health Care Conference
|
| Feb 19, 2010 |
Ethicon Endo-Surgery Announces Agreement with Hologic Inc. To Resolve Patent Disputes
|
| Feb 19, 2010 |
CHMP adopts negative opinion for ZEFTERA™
|
| Feb 17, 2010 |
New Study Compares Efficacy And Safety Of Once-Daily Versus Twice-Daily Prezista® Regimen In Treatment-Experienced Adult Patients With No Prezista Mutations
|
| Feb 16, 2010 |
Centocor Ortho Biotech Products and Amgen Finalize ESA Risk Evaluation and Mitigation Strategy (Rems) with FDA
|
| Feb 9, 2010 |
PREZISTA®* Now Approved as Part of Combination Therapy for Pediatric Patients Six Years of Age and Older with HIV
|
| Feb 4, 2010 |
Tapentadol Extended Release Data To Be Presented At American Academy Of Pain Medicine Annual Meeting
|
| Feb 1, 2010 |
Cordis Corporation Announces Agreement With Boston Scientific To Resolve Certain Coronary Stent Patent Disputes
|
| Jan 27, 2010 |
U.S. Food and Drug Administration Approves Labeling Update for PREZISTA® To Include 96-Week Data in HIV-1 Infected Adult Patients
|
| Jan 26, 2010 |
Johnson & Johnson Reports 2009 Fourth-Quarter and Full-Year Results:
|
| Jan 20, 2010 |
Ethicon Completes Acquisition of Acclarent
|
| Jan 19, 2010 |
Johnson & Johnson to Host Analyst Meeting to Discuss Fourth-Quarter and Full-Year 2009 Financial Results
|
| Jan 15, 2010 |
McNeil Consumer Healthcare Announces Voluntary Recall of Certain Over-the-Counter (OTC) Products in the Americas, UAE, and Fiji
|
| Jan 14, 2010 |
Stelara®* Shows Greater Efficacy than Etanercept for Treatment of Moderate-to-Severe Plaque Psoriasis
|
| Dec 30, 2009 |
FDA Issues Complete Response Letter for Ceftobiprole
|
| Dec 16, 2009 |
Ethicon Announces Definitive Agreement to Acquire Acclarent
|
| Dec 10, 2009 |
Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection
|
| Dec 6, 2009 |
Phase III Study of Rivaroxaban Shows That Extending Anticoagulant Treatment by Six or 12 Months Significantly Reduced Risk of Second Symptomatic VTE
|
| Dec 4, 2009 |
Janssen-Cilag Submits Marketing Authorisation Application in Europe for Paliperidone Palmitate for the Treatment of Schizophrenia
|
| Dec 1, 2009 |
New Drug Application Submitted to FDA for Tapentadol Extended Release Tablets for Management of Chronic Pain
|
| Nov 25, 2009 |
U.S. Food and Drug Administration (FDA) Grants Traditional Approval for INTELENCE® (ETRAVIRINE)
|
| Nov 23, 2009 |
ASP Announces Acquisition of Gloster Europe to Help Reduce Infections in Healthcare Facilities
|
| Nov 5, 2009 |
Johnson & Johnson to Participate in Credit Suisse 18th Annual Health Care Conference
|
| Nov 3, 2009 |
Johnson & Johnson Announces Restructuring Initiatives for Sustainable Growth
|
| Oct 22, 2009 |
Xerox Chairman Anne M. Mulcahy Appointed to Johnson & Johnson Board of Directors
|
| Oct 19, 2009 |
New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis
|
| Oct 19, 2009 |
New SIMPONI(TM) Data Show Inhibition of Joint Damage in Patients With Rheumatoid Arthritis and Psoriatic Arthritis
|
| Oct 15, 2009 |
Biosense Webster Receives FDA Clearance for the CARTO(R) 3 System
|
| Oct 14, 2009 |
Ortho Clinical Diagnostics Receives FDA Approval for First Anti-HIV 1+2 Test for Use on Random Access, Integrated Laboratory Testing System
|
| Oct 13, 2009 |
Johnson & Johnson Reports 2009 Third-Quarter Results:
|
| Oct 6, 2009 |
Johnson & Johnson to Host Analyst Meeting to Discuss Third-Quarter Financial Results and Review Medical Devices & Diagnostics Business
|
| Oct 6, 2009 |
Simponi™ (Golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis With Novel Smartject™ Autoinjector
|
| Sep 29, 2009 |
Cordis Corporation Announces Agreement with Boston Scientific to Settle Selected Stent Litigation Cases
|
| Sep 28, 2009 |
Johnson & Johnson and Crucell Announce Strategic Collaboration to Develop Innovative Products, Including Therapies for Influenza Prevention and Treatment
|
| Sep 25, 2009 |
STELARA ™ (ustekinumab) Receives FDA Approval For Treatment Of Moderate To Severe Plaque Psoriasis With Four-Times-A-Year Maintenance Dosing
|
| Sep 24, 2009 |
NEVO(TM) Sirolimus-Eluting Coronary Stent Associated with Significantly Less Chest Pain at Six Months Than Taxus(R) Liberte(R) Stent
|
| Sep 23, 2009 |
Janssen-Cilag's STELARA®▼ (ustekinumab) Approved by NICE for the Treatment of Moderate to Severe Plaque Psoriasis
|
| Sep 21, 2009 |
2.25 MM CYPHER(R) Sirolimus-eluting Coronary Stent Approved by FDA
|
| Sep 17, 2009 |
Johnson & Johnson and Elan Corporation plc Announce Closing of Transaction Related to Alzheimer's Immunotherapy Program and Equity Investment
|
| Sep 10, 2009 |
Centocor Ortho Biotech Receives FDA Complete Response Letter Regarding Doxil( R) for the Treatment of Advanced Breast Cancer
|
| Sep 10, 2009 |
FDA Issues Complete Response Letter for Trabectedin Combined with DOXIL
|
| Sep 8, 2009 |
Johnson & Johnson to Participate in Morgan Stanley Global Healthcare Unplugged Conference
|
| Aug 31, 2009 |
First Patient Enrolled in CYPRESS, a Dual Antiplatelet Therapy Trial with the CYPHER(R) Sirolimus-Eluting Coronary Stent
|
| Aug 21, 2009 |
FDA Issues Complete Response Letter for Carisbamate
|
| Aug 19, 2009 |
DePuy receives FDA Advisory Panel Recommendation for Pinnacle( R) CoMplete( TM) Acetabular Hip System
|
| Aug 3, 2009 |
Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia
|
| Jul 31, 2009 |
FDA Approves INVEGA( R) SUSTENNA( TM) for the Acute and Maintenance Treatment of Schizophrenia
|
| Jul 31, 2009 |
INVEGA( R) Approved as the First and Only Treatment for Schizoaffective Disorder
|
| Jul 21, 2009 |
FDA Approves Vitros( R) Anti-HCV Assay For Use On Vitros 5600( R) Integrated And Vitros 3600( R) Immunodiagnostic Systems
|
| Jul 21, 2009 |
Ortho Clinical Diagnostics Launches 24-Hour Remote Monitoring Center
|
| Jul 20, 2009 |
New HIV Study Shows That Large Numbers of Women and People of Color can be Successfully Enrolled in U.S. HIV Clinical Studies
|
| Jul 20, 2009 |
96-Week Safety and Efficacy Findings Presented for Intelencetm (Etravirine) as Part of HIV Combination Therapy
|
| Jul 16, 2009 |
Tibotec Pharmaceuticals Announces Agreement to Develop and Commercialize a New Fixed-Dose Combination of TMC278 and Truvada® with Gilead Sciences
|
| Jul 15, 2009 |
Centocor Ortho Biotech Statement on FDA ODAC Opinion Regarding Doxil( R) for Treatment of Advanced Breast Cancer
|
| Jul 15, 2009 |
Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding Trabectedin for Relapsed Ovarian Cancer
|
| Jul 14, 2009 |
Johnson & Johnson Reports 2009 Second-Quarter Results:
|
| Jul 10, 2009 |
Johnson & Johnson Completes Acquisition of Cougar Biotechnology
|
| Jul 7, 2009 |
Johnson & Johnson to Host Analyst Conference Call on Second-Quarter Results
|
| Jul 3, 2009 |
Johnson & Johnson Completes Initial Tender Offer for Cougar Biotechnology
|
| Jul 2, 2009 |
Johnson & Johnson and Elan Corporation plc Announce Definitive Agreement for Alzheimer's Immunotherapy Program and Equity Investment
|
| Jun 29, 2009 |
Centocor Ortho Biotech Inc. Awarded $1.67 Billion Patent Jury Verdict from Abbott Laboratories
|
| Jun 26, 2009 |
Simponi™ (Golimumab) Receives Positive Opinion From CHMP For Once-Monthly Subcutaneous Treatment Of Rheumatoid Arthritis, Psoriatic Arthritis And Ankylosing Spondylitis
|
| Jun 23, 2009 |
NUCYNTATM™(tapentadol) CII Immediate Release Tablets Now Available for Relief of Moderate to Severe Acute Pain
|
| Jun 17, 2009 |
Johnson & Johnson Announces Regulatory Clearance for Its Planned Acquisition of Cougar Biotechnology
|
| Jun 17, 2009 |
Unique Collaboration Between TB Alliance and Tibotec to Accelerate Tuberculosis Drug Development
|
| Jun 12, 2009 |
Biosense Webster to Support Landmark Clinical Trial of Atrial Fibrillation
|
| Jun 9, 2009 |
New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients
|
| Jun 9, 2009 |
Two-Year Data Show Patients Receiving SIMPONI(TM) (golimumab) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis
|
| Jun 5, 2009 |
Johnson & Johnson Begins Tender Offer to Acquire Cougar Biotechnology
|
| Jun 4, 2009 |
Johnson & Johnson Highlights Pharmaceutical Growth Strategies and Robust Pipeline to Address Unmet Medical Needs
|
| Jun 3, 2009 |
Data on Investigational Drug TMC207 for Treatment of MDR-Tuberculosis, Published in New England Journal of Medicine
|
| Jun 2, 2009 |
New One-Year Data from REMICADE(R) SONIC Trial Show Sustained Efficacy Compared with Azathioprine in Treatment of Crohn's Disease
|
| May 28, 2009 |
FDA Advisory Panel Recommends Approval of the SEDASYS® System
|
| May 28, 2009 |
Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
|
| May 28, 2009 |
FDA Issues Complete Response Letter for Rivaroxaban
|
| May 27, 2009 |
Johnson & Johnson Files Arbitration Demand Against Schering-Plough to Resolve Dispute Over Agreements for REMICADE(R) and SIMPONI(TM)
|
| May 27, 2009 |
Johnson & Johnson to Host Pharmaceutical Business Review
|
| May 26, 2009 |
FDA Extends Review Timeline for STELARA(TM) (ustekinumab) Biologic License Application by Three Months
|
| May 26, 2009 |
New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal
|
| May 21, 2009 |
Johnson & Johnson Announces Definitive Agreement to Acquire Cougar Biotechnology, Inc.
|
| May 19, 2009 |
RISPERDAL® CONSTA® (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder
|
| May 19, 2009 |
New Data Demonstrate RISPERDAL® CONSTA® (Risperidone) Long-Acting Treatment May Improve Health Outcomes and Reduce Hospitalizations in Patients with Schizophrenia
|
| May 19, 2009 |
In Patients with Heart Attacks, CYPHER(R) Sirolimus-Eluting Coronary Stent Results Sustained out to Four Years Compared to Bare Metal Stents
|
| May 19, 2009 |
NEVO(TM) Sirolimus-Eluting Coronary Stent Yields Superior Results to Taxus(R) Liberte(R) Stent in Pivotal Clinical Trial
|
| May 18, 2009 |
FDA Grants Approval for Use of RISPERDAL® CONSTA® as Both a Monotherapy and Adjunctive Therapy in the Maintenance Treatment of Bipolar I Disorder
|
| May 14, 2009 |
Benefits of Catheter Ablation with the NAVISTAR(R) THERMOCOOL(R) Catheter Sustained for One Year in the Treatment of Symptomatic, Paroxysmal Atrial Fibrillation
|
| May 13, 2009 |
Retrospective Analysis Finds Treatment of Cancer Chemotherapy Patients with Epoetin Alfa Associated with Lower Drug Cost than Darbepoetin Alfa
|
| May 13, 2009 |
Biosense Webster to Showcase Advanced Ablation Technologies for Electrophysiologists at HRS 2009
|
| May 13, 2009 |
Johnson & Johnson to Participate in Deutsche Bank 34th Annual Health Care Conference
|
| May 12, 2009 |
Johnson & Johnson to Host Analyst Conference Call To Review Six-Month Trial Results From NEVO RES I
|
| May 7, 2009 |
Johnson & Johnson Announces Support for Kohl-Grassley Physician Payments Sunshine Act of 2009
|
| May 7, 2009 |
Cellsearch® System to be Offered at Florida Cancer Specialists
|
| May 7, 2009 |
Three Clinical Presentations on Tapentadol Extended Release Tablets for Chronic Pain Featured at 2009 American Pain Society Annual Meeting
|
| May 5, 2009 |
Johnson & Johnson to Participate in Bank of America and Merrill Lynch 2009 Health Care Conference
|
| Apr 24, 2009 |
Simponi (Golimumab) Receives FDA Approval As First Once-Monthly Anti-TNF For Treatment Of Rheumatoid Arthritis, Psoriatic Arthritis
|
| Apr 23, 2009 |
Johnson & Johnson Announces Dividend Increase of 6.5%
|
| Apr 22, 2009 |
Ethicon Endo-Surgery Novel Investigational Notes and SSL Devices Featured In 15 Presentations At SAGES
|
| Apr 22, 2009 |
FDA Grants Ethicon Endo-Surgery Approval of its IDE Application to Commence Study of Notes Toolbox™
|
| Apr 21, 2009 |
Virco Lab, Inc. enters into Collaboration with SmartGene, Inc. enhancing HIV resistance test services for laboratories and physicians
|
| Apr 16, 2009 |
Johnson & Johnson to Webcast Annual Meeting of Shareholders
|
| Apr 14, 2009 |
Johnson & Johnson Reports 2009 First-Quarter Results
|
| Apr 13, 2009 |
Health Canada Approves Simponi™ (Golimumab) For Treatment Of Rheumatoid Arthritis, Psoriatic Arthritis And Ankylosing Spondylitis
|
| Apr 9, 2009 |
New Clinical Data at ACC09 Show the CYPHER(R) Sirolimus-eluting Coronary Stent Outperformed TAXUS(R) LIBERTE(R) and ENDEAVOR(R) Stents in Key Outcome Measures
|
| Apr 7, 2009 |
Health Canada Approves PREZISTA* Once Daily as Part of Combination Therapy for Treatment-Naive Adults with HIV-1
|
| Apr 7, 2009 |
Johnson & Johnson to Host Analyst Conference Call on First-Quarter Results
|
| Apr 1, 2009 |
Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder
|
| Mar 31, 2009 |
District Court Decision Received in CONCERTA® Patent Case
|
| Mar 23, 2009 |
U.S. FDA Approves New THERAKOS™ CELLEX™ Photopheresis System
|
| Mar 19, 2009 |
FDA Advisory Committee Finds Favorable Risk-Benefit Profile for Oral Anticoagulant Rivaroxaban for Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism after Hip or Knee Replacement Surgery
|
| Mar 16, 2009 |
Cordis Corporation Announces Head-to-Head Randomized Clinical Trial Comparing the NEVO(TM) Sirolimus-Eluting Coronary Stent to the XIENCE(TM) Stent
|
| Mar 12, 2009 |
Johnson & Johnson to Provide Webcast Presentation of Tapentadol Extended Release (ER) Phase 3 Clinical Data Presented at World Institute of Pain 5th Annual World Congress
|
| Mar 10, 2009 |
Johnson & Johnson to Participate in the 29th Annual Cowen & Company Health Care Conference
|
| Mar 5, 2009 |
CYPHER(R) Sirolimus-eluting Coronary Stent Demonstrates Sustained Benefits Compared to Bare-Metal Stents in Six-Year Randomized Clinical Trial
|
| Feb 24, 2009 |
CHMP delays European Commission decision process to approve ZEVTERA
|
| Feb 10, 2009 |
FDA Issues Complete Response Letter for RISPERDAL(R) CONSTA(R) for the Adjunctive Maintenance Treatment of Bipolar Disorder
|
| Feb 10, 2009 |
Priligy™ (Dapoxetine) Receives First Regulatory Approvals for the Treatment of Premature Ejaculation (PE) in Finland and Sweden
|
| Feb 6, 2009 |
FDA Grants Marketing Approval to NAVISTAR(R) THERMOCOOL(R) Catheter for Atrial Fibrillation
|
| Feb 6, 2009 |
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Announces FDA Filings for Paliperidone Palmitate and INVEGA(R)
|
| Feb 5, 2009 |
Tibotec Submits Application to U.S. Food and Drug Administration Seeking Traditional Approval for INTELENCE (etravirine)
|
| Feb 3, 2009 |
Once-Daily Prezista® (darunavir) for Treatment-Naïve Adults with HIV-1 Receives Approval in the European Union as Part of Combination Therapy
|
| Jan 28, 2009 |
Health Canada Clears New Therakos Cellex Photopheresis System
|
| Jan 23, 2009 |
Johnson & Johnson Completes Acquisition of Mentor Corporation
|
| Jan 23, 2009 |
Johnson & Johnson Completes Tender Offer for Mentor Corporation
|
| Jan 22, 2009 |
NEW BIOLOGIC STELARA™ RECEIVES APPROVAL IN EUROPE FOR TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS
|
| Jan 20, 2009 |
Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results
|
| Jan 17, 2009 |
Johnson & Johnson Completes Initial Tender Offer for Mentor Corporation with 92.9% of Shares Tendered
|
| Jan 15, 2009 |
Johnson & Johnson Announces Satisfaction of Regulatory Clearances Condition for its Proposed Acquisition of Mentor Corporation
|
| Jan 15, 2009 |
Court of Appeals Overturns 2005 Patent Verdict Against Cordis
|
| Jan 13, 2009 |
Johnson & Johnson to Review Fourth-Quarter and Full-Year 2008 Financial Results
|
| Jan 6, 2009 |
Johnson & Johnson Extends Tender Offer for Mentor Corporation
|
| Dec 30, 2008 |
Johnson & Johnson Completes Acquisition of Omrix Biopharmaceuticals, Inc.
|
| Dec 27, 2008 |
Johnson & Johnson Completes Tender Offer for Omrix Biopharmaceuticals, Inc.
|
| Dec 23, 2008 |
VITROS® 3600 Immunodiagnostic System for Laboratory Diagnostics Receives 510(K) Clearance from the FDA
|
| Dec 19, 2008 |
Johnson & Johnson Extends Tender Offer for Omrix Biopharmaceuticals, Inc.
|
| Dec 19, 2008 |
Johnson & Johnson Strengthens Wellness & Prevention Platform with Acquisition of Human Performance Institute(TM)
|
| Dec 19, 2008 |
FDA Issues Complete Response Letter to Centocor for Ustekinumab Biologic License Application
|
| Dec 16, 2008 |
ETHICON Launches the Latest Innovation in Hernia Repair Platform
|
| Dec 15, 2008 |
Approval of STELARATM in Canada Marks Advancement in Treatment of Moderate to Severe Plaque Psoriasis
|
| Dec 14, 2008 |
Study Finds DOXIL® Combination Therapy Delays Disease Progression for Patients with Metastatic Breast Cancer
|
| Dec 12, 2008 |
Johnson & Johnson Begins Tender Offer to Acquire Mentor Corporation
|
| Dec 11, 2008 |
Johnson & Johnson Announces Receipt of Israeli Antitrust Approval for Acquisition of Omrix
|
| Dec 9, 2008 |
Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia
|
| Dec 9, 2008 |
Velcade® (Bortezomib) Findings Reinforce Efficacy And Survival Across Multiple Patient Populations
|
| Dec 7, 2008 |
Rivaroxaban Reduces Symptomatic VTE & Death Following Knee or Hip Replacement Surgery by More Than 50% Compared to Enoxaparin in Pooled Analysis of the RECORD Clinical Trial Program
|
| Dec 6, 2008 |
Phase III Data Demonstrates Efficacy and Tolerability of Carisbamate as an Adjunctive Therapy for Partial Onset Seizures
|
| Dec 6, 2008 |
Observational Study Finds Changes in Medicare Reimbursement for Erythropoiesis-stimulating Agents Associated with Increased Need for Blood Transfusion
|
| Dec 3, 2008 |
Tibotec and Emcure Collaborate on Access to Darunavir for India
|
| Dec 3, 2008 |
Prezista® (Darunavir) Receives Expanded Marketing Authorisation In The European Union For Treatment-Experienced Adults With HIV-1
|
| Dec 1, 2008 |
ETHICON Completes Divestiture of Professional Wound Care Business to One Equity Partners
|
| Dec 1, 2008 |
Johnson & Johnson Announces Definitive Agreement to Acquire Mentor Corporation
|
| Nov 27, 2008 |
European Committee for Human Medicinal Products (CHMP) Issues Positive Opinion For Once-Daily PREZISTA® (darunavir) as Part of Combination Therapy for Treatment-Naïve Adults With HIV-1
|
| Nov 26, 2008 |
FDA Issues Complete Response Letter for Ceftobiprole for Treatment of Complicated Skin Infections
|
| Nov 25, 2008 |
Johnson & Johnson Begins Tender Offer to Acquire Omrix
|
| Nov 24, 2008 |
Johnson & Johnson Announces Definitive Agreement to Acquire Omrix
|
| Nov 21, 2008 |
New Antibiotic Against Serious Infections
|
| Nov 21, 2008 |
FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain
|
| Nov 20, 2008 |
European Agency for the Evaluation of Medicinal Products Recommends Suspension of Marketing Authorisation for IONSYS®
|
| Nov 20, 2008 |
FDA Advisory Panel Unanimously Recommends Approval of NAVISTAR® THERMOCOOL® Catheter for Atrial Fibrillation
|
| Nov 20, 2008 |
Tibotec Begins Enrollment in Europe for Phase III Trial of Telaprevir in HCV Patients who Failed Prior Treatment
|
| Nov 20, 2008 |
Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008
|
| Nov 20, 2008 |
Ortho Biotech Announces NDA Submission for Trabectedin for the Treatment of Relapsed Ovarian Cancer
|
| Nov 18, 2008 |
Long-Term Titan Study Evaluates Prezista®/Ritonavir vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Experienced Adults
|
| Nov 18, 2008 |
Magnetically Steered Irrigated Tip Cardiac Catheter for Treatment of Irregular Heart Rhythms Now Available Throughout the European Union
|
| Nov 13, 2008 |
New Antibiotic Against Serious Infections - Receives First Approval in Europe
|
| Nov 12, 2008 |
Tibotec Data Presented at ICAAC and HIV9 Follow key Regulatory Approvals for Anti-HIV Compounds
|
| Nov 11, 2008 |
Study Finds Catheter Ablation with the NAVISTAR(R) THERMOCOOL(R) Catheter Superior to Anti-Arrhythmic Drug Therapy for the Treatment of Symptomatic, Paroxysmal Atrial Fibrillation
|
| Nov 10, 2008 |
Johnson & Johnson-Merck Consumer Pharmaceuticals Company Announces Urgent Voluntary Nationwide Recall of Infants' MYLICON(R) GAS RELIEF DYE FREE Drops (Simethicone-Antigas) Non-Staining Due to Possible Metal Fragments
|
| Nov 6, 2008 |
Johnson & Johnson to Participate in Credit Suisse 2008 Health Care Conference
|
| Nov 1, 2008 |
Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder
|
| Oct 30, 2008 |
TCT2008 Concludes with Presentation of Positive Data for the CYPHER(R) Sirolimus-eluting Coronary Stent
|
| Oct 27, 2008 |
Johnson & Johnson Establishes Wellness & Prevention Platform with Acquisition of HealthMedia, Inc.
|
| Oct 27, 2008 |
New Data Show In Vitro Potency of Doripenem Against Resistant Bacteria
|
| Oct 27, 2008 |
Golimumab Phase 3 Data Show Significant Improvement in Physical Function in Patients with Rheumatoid Arthritis
|
| Oct 27, 2008 |
Patient Enrollment Complete for Pivotal Trial of the NEVO(TM) Sirolimus-eluting Coronary Stent with Unique Reservoir Technology
|
| Oct 27, 2008 |
One-Year Data Show Golimumab Improved Signs and Symptoms in Patients with Psoriatic Arthritis in Phase 3 Study
|
| Oct 24, 2008 |
FDA Clears VITROS® 5600 Integrated System for Laboratory Diagnostics
|
| Oct 24, 2008 |
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Submits New Drug Application to FDA for Carisbamate
|
| Oct 22, 2008 |
U.S. Food and Drug Administration (FDA) Approves PREZISTA® Once-Daily as Part of Combination Therapy for Treatment-Naïve Adults with HIV-1
|
| Oct 17, 2008 |
Ethicon Endo-Surgery Completes Acquisition of SurgRx, Inc.
|
| Oct 15, 2008 |
Tibotec Begins Enrollment for Phase III Study of Telaprevir, an Investigational Agent, in HCV Patients Who Failed Prior Treatment
|
| Oct 14, 2008 |
Johnson & Johnson Reports 2008 Third-Quarter Results
|
| Oct 9, 2008 |
FDA Approves New Injection Site for RISPERDAL(R) CONSTA(R) for Schizophrenia Treatment
|
| Oct 9, 2008 |
Johnson & Johnson Announces Executive Appointments: Sheri McCoy, Worldwide Chairman, Pharmaceuticals Group, and Alex Gorsky, Worldwide Chairman, Surgical Care Group
|
| Oct 7, 2008 |
McNeil Consumer Healthcare Supports Voluntary Initiatives To Help Encourage Safe, Effective Use Of Children's Cough And Cold Medicines
|
| Oct 7, 2008 |
Johnson & Johnson to Host Analyst Meeting to Discuss Third-Quarter Financial Results and Review Pharmaceutical Business
|
| Sep 30, 2008 |
U.S. District Court in Delaware Enters Final Judgment of Approximately $1.2 Billion to Cordis Corporation on Patents Infringed by Medtronic, Inc. and Boston Scientific Corporation
|
| Sep 18, 2008 |
Findings from Landmark Study show Ustekinumab Demonstrated Superior Efficacy to Enbrel® (Etanercept) in Treatment of Moderate to Severe Plaque Psoriasis
|
| Sep 17, 2008 |
Preliminary Data from Experimental Study Demonstrate Increased Mortality in Stroke Patients Treated With Epoetin Alfa
|
| Sep 15, 2008 |
U.S. District Court in Delaware Reinstates Damage Awards to Cordis Corporation on Patents Infringed by Medtronic, Inc. and Boston Scientific Corporation
|
| Sep 12, 2008 |
Christine A. Poon Plans Retirement from Johnson & Johnson in Early 2009
|
| Sep 8, 2008 |
Ortho Biotech Files sNDA for DOXIL® for the Treatment of Advanced Breast Cancer
|
| Sep 8, 2008 |
VELCADE* for multiple myeloma receives front-line approval in Canada
|
| Sep 8, 2008 |
VELCADE® (bortezomib) Approved For Previously Untreated Multiple Myeloma
|
| Sep 4, 2008 |
Clinical Data Indicate that Percutaneous Coronary Intervention with the CYPHER(R) Sirolimus-eluting Coronary Stent Is Comparable to Bypass Surgery in Key Safety Measures in Patients with Diabetes and Multi-Vessel Disease
|
| Sep 2, 2008 |
First Patient Enrolled in Study Evaluating S.M.A.R.T. (R) Nitinol Self-Expandable Stent System in Leg Disease
|
| Aug 29, 2008 |
INTELENCETM (etravirine) RECEIVES MARKETING AUTHORISATION IN THE EUROPEAN UNION FOR HIV COMBINATION THERAPY
|
| Aug 28, 2008 |
Ortho-McNeil Neurologics to Appeal Patent Ruling on RAZADYNE(R)
|
| Aug 28, 2008 |
The CYPHER(R) Sirolimus-eluting Coronary Stent Outperforms the Taxus(R) Stent in People with Diabetes According to Clinical Data in the Journal of the American College of Cardiology
|
| Aug 27, 2008 |
CYPHER SELECT(R) Plus Sirolimus-eluting Coronary Stent Receives CE Mark Approval for Treatment of Heart Attacks
|
| Aug 26, 2008 |
FDA Issues Complete Response Letter for Paliperidone Palmitate for the Treatment of Schizophrenia
|
| Aug 21, 2008 |
FDA Requires Additional Information on Doribax for Treatment of Hospital-Acquired Pneumonia
|
| Aug 11, 2008 |
Ethicon Endo-Surgery To Acquire SurgRx
|
| Aug 8, 2008 |
FDA EXTENDS REVIEW TIMELINE FOR USTEKINUMAB BIOLOGIC LICENSE APPLICATION THREE MONTHS
|
| Aug 5, 2008 |
Ninety-Six Week Data On Tibotec Investigational NNRTI, TMC278, Presented At AIDS 2008
|
| Aug 1, 2008 |
Veridex Completes Acquisition of Immunicon Corporation Assets
|
| Jul 30, 2008 |
Johnson & Johnson (China) Investment Co., Ltd. Acquires Beijing Dabao Cosmetics Co., Ltd.
|
| Jul 30, 2008 |
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Submits New Drug Application to FDA for Rivaroxaban
|
| Jul 25, 2008 |
FDA Grants Pediatric Exclusivity for TOPAMAX®
|
| Jul 16, 2008 |
FDA Advisory Committee Provides Opinion of DORIBAX(TM) for the Treatment of Hospital-Acquired Pneumonia
|
| Jul 15, 2008 |
Johnson & Johnson Reports 2008 Second-Quarter Results:
|
| Jul 10, 2008 |
Johnson & Johnson Announces Commitment To Adopt Revised PhRMA Marketing Code for Responsible Interactions With Healthcare Professionals
|
| Jul 8, 2008 |
Johnson & Johnson to Host Analyst Conference Call on Second-Quarter Results
|
| Jul 1, 2008 |
OneTouch® PingTM Glucose Management System Cleared by FDA
|
| Jul 1, 2008 |
ETHICON Receives Offer from One Equity Partners to Purchase Professional Wound Care Business
|
| Jun 30, 2008 |
Janssen Announces Launch of Authorized Generic for RISPERDAL(R)
|
| Jun 30, 2008 |
FDA Approves EVOLENCE®, a New Generation Collagen-Based Facial Filler
|
| Jun 27, 2008 |
FDA Approves CONCERTA(R) (methylphenidate HCI) Extended-release Tablets for Treatment of ADHD (Attention Deficit Hyperactivity Disorder) in Adults
|
| Jun 18, 2008 |
Johnson & Johnson Nordic AB Acquires Amic
|
| Jun 17, 2008 |
FDA Advisory Committee Unanimously Recommends Approval of Ustekinumab for Treatment of Moderate To Severe Plaque Psoriasis
|
| Jun 6, 2008 |
Johnson & Johnson to Participate in 29th Annual Goldman Sachs Global Healthcare Conference
|
| Jun 5, 2008 |
Johnson & Johnson Reviews Growth Strategies for Medical Devices & Diagnostics and Consumer Businesses
|
| May 30, 2008 |
Rivaroxaban Superior to U.S.-Approved Dosing Regimen for Enoxaparin in Reducing Venous Blood Clots after Total Knee Replacement Surgery in Pivotal Phase III Trial
|
| May 29, 2008 |
Johnson & Johnson to Host Medical Devices & Diagnostics and Consumer Business Review
|
| May 15, 2008 |
Johnson & Johnson to Participate in Citi's Global Healthcare Conference
|
| May 13, 2008 |
Biosense Webster Presents ''Complete Ablation Solutions'' to Electrophysiologists at Heart Rhythm 2008
|
| May 13, 2008 |
State-of-the-Art Cobalt Chromium Bare Metal Stent Now Available in Europe
|
| May 9, 2008 |
New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective For Acute Pain From Common Foot Surgery
|
| May 9, 2008 |
New Study Suggests Tapentadol IR For Acute Pain Is Associated With Improved Gastrointestinal Tolerability Compared To Oxycodone IR
|
| May 9, 2008 |
Results Of Phase 3 Study Show Tapentadol Ir Relieves Acute Pain And Offers Favorable Gastrointestinal Tolerability Profile
|
| May 7, 2008 |
Johnson & Johnson to Provide Webcast Presentation of Tapentadol Phase 3 Clinical Data Presented at American Pain Society's Annual Meeting
|
| Apr 29, 2008 |
Johnson & Johnson to Participate in Deutsche Bank Health Care Conference
|
| Apr 25, 2008 |
Johnson & Johnson to Participate in Morgan Stanley Conference
|
| Apr 24, 2008 |
Johnson & Johnson Announces Dividend Increase of 10.8%
|
| Apr 22, 2008 |
Johnson & Johnson to Webcast Annual Meeting of Shareholders
|
| Apr 15, 2008 |
Johnson & Johnson Reports 2008 First-Quarter Results:
|
| Apr 11, 2008 |
Ortho Biotech Oncology Research & Development Unites
Johnson & Johnson Biopharmaceutical Oncology R&D Assets
|
| Apr 9, 2008 |
NEJM Study Demonstrates Carotid Stenting with Embolic Protection is Comparable to Surgery
|
| Apr 8, 2008 |
Johnson & Johnson to Host Analyst Conference Call on First-Quarter Results
|
| Apr 4, 2008 |
Data From Ortho Biotech-Sponsored Studies To Be Presented At National Kidney Foundation 2008 Spring Clinical Meetings
|
| Apr 1, 2008 |
First New NNRTI in Nearly a Decade to Benefit Canadians with HIV/AIDS
|
| Mar 30, 2008 |
Three Year Follow-up Data Suggest Better Outcomes Were Maintained with the CYPHER(R) Sirolimus-Eluting Coronary Stent Compared to Brachytherapy in Patients with In-Stent Reblockage
|
| Mar 28, 2008 |
Ortho-Clinical Diagnostics Receives FDA Approval for New HIV Test
|
| Mar 27, 2008 |
Clinical Trial Begins for Innovative Drug-Eluting Stent with Unique Reservoir Technology
|
| Mar 27, 2008 |
Ethicon Endo-Surgery Submits Application to FDA for Approval of the Sedasys System - The First Computer-Assisted Personalized Sedation System
|
| Mar 21, 2008 |
Relief "In Sight" For Allergy Sufferers
|
| Mar 19, 2008 |
Centocor, Inc. And Schering-Plough Submit Application Requesting Approval Of Golimumab In Europe For The Treatment Of Rheumatoid Arthritis, Psoriatic Arthritis And Ankylosing Spondylitis
|
| Mar 18, 2008 |
FDA Issues Approvable Letter for Ceftobiprole for Treatment of Complicated Skin Infections
|
| Mar 17, 2008 |
Cordis Corporation Receives U.S. Food and Drug Administration Clearance for S.M.A.R.T. Nitinol Stent Transhepatic Biliary System for 120 mm and 150 mm Lengths
|
| Mar 17, 2008 |
Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote
|
| Mar 13, 2008 |
Johnson & Johnson to Participate in the 28th Annual Cowen & Company Health Care Conference
|
| Mar 11, 2008 |
Totality of Available Data Reaffirms PROCRIT® (Epoetin alfa) Safe and Effective When Used Appropriately As Labeled to Treat Chemotherapy-Induced Anemia
|
| Mar 11, 2008 |
Johnson & Johnson to Participate in Lehman Brothers Eleventh Annual Global Healthcare Conference
|
| Mar 7, 2008 |
Ortho Biotech Modifies Prescribing Information for PROCRIT® (Epoetin alfa)
|
| Mar 6, 2008 |
FDA Extends Review Timeline for Additional Indication for Antibiotic DORIBAX(TM)
|
| Feb 27, 2008 |
FDA CLEARS CELLSEARCH™ CIRCULATING TUMOR CELL TEST
|
| Feb 27, 2008 |
DePuy to Host Analyst Meeting
|
| Feb 12, 2008 |
PRICARA RECALLS 25 mcg/hr DURAGESIC® (fentanyl transdermal system) CII PAIN PATCHES
|
| Feb 7, 2008 |
New 48-Week Efficacy and Safety Data Presented for Intelencetm (Etravirine) As Part of HIV Combination Therapy
|
| Feb 4, 2008 |
Promising Phase 3 Data for Ustekinumab (Cnto 1275) in Long-Term Improvement of Chronic Plaque Psoriasis
|
| Feb 4, 2008 |
Centocor Announces Ustekinumab Biologic License Application Accepted For Filing By FDA
|
| Feb 4, 2008 |
Study Suggests Risperidone Long-Acting Injection Combined with Standard Treatment Helped Delay Time to Relapse in Patients with Bipolar Disorder
|
| Jan 23, 2008 |
New Drug Application Submitted to FDA for Investigational Analgesic Tapentadol Immediate Release Tablets
|
| Jan 22, 2008 |
Johnson & Johnson Reports Fourth-Quarter and Full-Year 2007 Results
|
| Jan 18, 2008 |
FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy
|
| Jan 15, 2008 |
Johnson & Johnson to Review Fourth-Quarter and Full-Year 2007 Financial Results
|
| Jan 14, 2008 |
IONSYS, the highly innovative needle-free system for the management of acute post-operative pain, available in Germany, the UK and Ireland
|
| Jan 7, 2008 |
Court of Appeals Upholds Verdicts in Favor of Cordis Corporation on Patents Infringed by Medtronic, Inc. and Boston Scientific Corporation
|
| Dec 21, 2007 |
Supplemental New Drug Application for PREZISTA Submitted to U.S. Food and Drug Administration
|
| Dec 21, 2007 |
Centocor Inc., Schering-Plough Corporation Revise Agreement Covering REMICADE®, Golimumab
|
| Dec 21, 2007 |
Submission of Marketing Authorisation Application for VELCADE® (bortezomib) in Europe
|
| Dec 12, 2007 |
INVEGA Shows Favorable Long-Term Safety Profile in a One Year Study of Patients With Schizophrenia
|
| Dec 10, 2007 |
Three Phase III Trials Show Rivaroxaban Outperformed Enoxaparin in Preventing Venous Thromboembolism After Major Orthopedic Surgery
|
| Dec 8, 2007 |
Pivotal Phase III Data Showed Rivaroxaban Was Statistically Superior to Enoxaparin in Preventing Venous Thromboembolism (VTE) in Patients Following Hip Replacement Surgery
|
| Dec 4, 2007 |
Centocor and Janssen-Cilag announced the submission of the US and European filings for ustekinumab (CNTO 1275) for the treatment of adult patients with chronic moderate to severe plaque psoriasis.
|
| Nov 16, 2007 |
FDA Approves the Allergy Treatment Zyrtec® for Use Without a Prescription
|
| Nov 15, 2007 |
Johnson & Johnson Announces Changes to Accelerate Growth
|
| Nov 9, 2007 |
New Phase III Trial Results for Rivaroxaban to be Presented at the 49th Annual Meeting of the American Society of Hematology
|
| Nov 6, 2007 |
Johnson & Johnson to Present at the Credit Suisse 2007 Healthcare Conference
|
| Nov 5, 2007 |
Pooled Analysis Of Long-Term Data Suggests CYPHER® Sirolimus-Eluting Coronary Stent Provides Sustained Clinical Benefits In Patients With Coronary Artery Disease Compared To Bare Metal Stents
|
| Nov 1, 2007 |
Johnson & Johnson to Host Analyst Meeting to Discuss Three Late-Stage Pipeline Compounds Presented at American College of Rheumatology (ACR) Conference
|
| Oct 29, 2007 |
Johnson & Johnson Pharmaceutical Research & Development Submits New Drug Application for Paliperidone Palmitate
|
| Oct 26, 2007 |
New Study of Concerta(R) Showed Significant Improvement of ADHD Symptom Management in Adults Compared to Placebo
|
| Oct 23, 2007 |
Adoption of Drug-Eluting Stents Associated With Lower Health Care Costs and Improved Clinical Outcomes
|
| Oct 23, 2007 |
Next Generation New Devices to Treat Clogged Neck Arteries Launched in U.S. and Europe
|
| Oct 22, 2007 |
New Long-Term Data Suggest Clinical Differences in Safety and Efficacy Between CYPHER® Sirolimus-Eluting Coronary Stent and Taxus Stent
|
| Oct 21, 2007 |
New Study Shows Excellent Outcomes for CYPHER® Sirolimus-Eluting Coronary Stent in Treatment of Completely Blocked Coronary Arteries
|
| Oct 17, 2007 |
Cordis Corporation Announces Clinical Studies And Events At TCT 2007
|
| Oct 16, 2007 |
Johnson & Johnson Launches Global Diabetes Institute to Provide State-of-The- Art Education, Training to Health Professionals
|
| Oct 16, 2007 |
Johnson & Johnson Reports 2007 Third-Quarter Results: Sales of $15.0 Billion Increased 12.7%; EPS was $.88, Including Special Charges; Excluding Special Charges, EPS was $1.06 *
|
| Oct 15, 2007 |
FDA Approves DORIBAX for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections
|
| Oct 13, 2007 |
INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients
|
| Oct 11, 2007 |
McNeil Consumer Healthcare Is Voluntarily Withdrawing Infants' Cough And Cold Products: CONCENTRATED TYLENOL® INFANTS' DROPS PLUS COLD, CONCENTRATED TYLENOL® INFANTS' DROPS PLUS C
|
| Oct 10, 2007 |
Johnson & Johnson to Host Analyst Meeting to Discuss Third-Quarter Financial Results and Review Its Medical Device & Diagnostics Business
|
| Oct 9, 2007 |
New HARMONIC FOCUS Provides Advantages in Surgical Efficiency, Performance and Patient Outcomes
|
| Oct 8, 2007 |
New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients with Diabetic Foot Infections
|
| Oct 8, 2007 |
Topline Findings from Comparative Analysis of INVEGA(TM) and Quetiapine in Schizophrenia to be Postered at the 20th Annual U.S. Psychiatric and Mental Health Congress
|
| Oct 3, 2007 |
Ortho-Clinical Diagnostics Introduces Improved Sensitivity Troponin I Assay To Help Diagnose Heart Attack, Heart Damage
|
| Sep 27, 2007 |
Statement of DePuy Orthopaedics, Inc. Regarding Agreement with U.S. Attorney's Office
|
| Sep 25, 2007 |
Pivotal Ustekinumab (CNTO 1275) Phase 3 Data to Debut at World Congress of Dermatology Meeting
|
| Sep 20, 2007 |
FDA Accepts New Drug Application For Priority Review Of Investigational HIV Treatment TMC125
|
| Sep 20, 2007 |
Johnson Statement on Litigation with the American Red Cross
|
| Sep 18, 2007 |
New Phase 3 Study In Treatment-Naïve Adults With HIV Evaluates Efficacy And Safety Of Once-Daily PREZISTA™/Ritonavir Vs. Kaletra® As Part Of HIV Combination Therapy
|
| Sep 18, 2007 |
New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients With Complicated Skin Infections, Including MRSA
|
| Sep 18, 2007 |
New Data Show Doripenem as Effective as Commonly Used Therapies in Treating Hospital-Acquired Pneumonias
|
| Sep 17, 2007 |
FDA Approves LEVAQUIN® Short-Course Therapy for Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis
|
| Sep 13, 2007 |
Largest Study To Date Finds Drug-Eluting Stents And Bare-Metal Stents Yield Similarly Low Mortality Rates
|
| Sep 12, 2007 |
Ortho Biotech Reiterates Confidence in PROCRIT® (Epoetin alfa) Safety and Efficacy When Used According to Label
|
| Sep 11, 2007 |
Ortho Biotech Reiterates Confidence in PROCRIT® (Epoetin alfa) Safety and Efficacy When Used According to Label
|
| Sep 5, 2007 |
Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
|
| Sep 4, 2007 |
Johnson & Johnson to Participate in Bear Stearns 20th Annual Healthcare Conference
|
| Sep 4, 2007 |
Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
|
| Sep 3, 2007 |
Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
|
| Aug 22, 2007 |
FDA Approves RISPERDAL® to Treat Adolescents With Schizophrenia and Children and Adolescents With Bipolar Mania
|
| Aug 8, 2007 |
Johnson & Johnson Statement on Civil Complaint Against The American National Red Cross and Commercial Licensees
|
| Jul 31, 2007 |
Johnson & Johnson Plans to Improve Overall Cost Structure, While Continuing to Invest in Opportunities for Sustained Profitable Growth
|
| Jul 19, 2007 |
Ortho-McNeil, Inc., Settles Patent Infringement Litigation Against Par/Kali
|
| Jul 18, 2007 |
New Drug Application for Investigational HIV Treatment TMC125 Submitted to U.S. Food and Drug Administration
|
| Jul 17, 2007 |
Johnson & Johnson Reports 2007 Second-Quarter Results: Sales Increase of 13.2% and EPS increase of 10.5% Versus a Year Ago; Excluding Special Charges in 2006, EPS increased 7.1%*
|
| Jul 17, 2007 |
FDA Approves First Gene-Based Test To Detect The Spread Of Breast Cancer Into Lymph Nodes
|
| Jul 11, 2007 |
Johnson & Johnson to Host Analyst Conference Call on Second-Quarter Results
|
| Jul 9, 2007 |
Johnson & Johnson Announces $10 Billion Share Repurchase Program
|
| Jul 8, 2007 |
Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
|
| Jul 6, 2007 |
TMC125 Demonstrates Significant Efficacy in Treatment-Experienced Patients with NNRTI Resistance in Phase III trials
|
| Jul 6, 2007 |
New PREZISTA® Phase III Study meets primary objective of non-inferiority and secondary objective of superiority in virologic response vs. KALETRA® in treatment-experienced HIV patients
|
| Jun 28, 2007 |
INVEGA Receives Marketing Authorization In European Union For Treatment Of Schizophrenia
|
| Jun 28, 2007 |
World Council of Optometry Awards ACUVUE(R) ADVANCE(TM), ACUVUE(R) OASYS(TM) Brands With Global Seal of Acceptance for UV Absorbing Contact Lenses
|
| Jun 21, 2007 |
FDA Issues Approvable Letter for RISPERDAL(R) to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar Mania
|
| Jun 14, 2007 |
Johnson & Johnson Invites Nominations for the 2008 Dr. Paul Janssen Award for Biomedical Research
|
| Jun 14, 2007 |
Cordis Corporation Resolves Corporate Warning Letter
|
| Jun 12, 2007 |
William D. Perez of Wm. Wrigley Jr. Company Appointed to Johnson & Johnson Board of Directors
|
| Jun 7, 2007 |
New Balloon Catheter Available Worldwide for Carotid and Renal Angioplasty Procedures
|
| Jun 7, 2007 |
Johnson & Johnson Highlights Growth Strategies for Pharmaceutical and Consumer Businesses
|
| Jun 6, 2007 |
New Drug Application Submitted for Investigational Antibiotic Doripenem
|
| Jun 6, 2007 |
VISTAKON(R) Launches Electronic Contact Lens Reminder Service to Help Improve Contact Lens Compliance
|
| Jun 4, 2007 |
New Study Suggests Better Patient Outcomes with CYPHER(R) Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings
|
| May 29, 2007 |
Johnson & Johnson To Host Pharmaceutical and Consumer Business Review
|
| May 22, 2007 |
CYPHER(R) Sirolimus-Eluting Coronary Stent Had Similar Results to Bypass Surgery and Better Outcomes Than Bare Metal Stents in Subgroup Analysis of Diabetic Patients With Multivessel Coronary Disease
|
| May 21, 2007 |
Johnson & Johnson to Participate in Bank of America 2007 Health Care Conference
|
| May 18, 2007 |
New Drug Application Submitted For Novel Investigational Antibiotic Ceftobiprole
|
| May 16, 2007 |
Johnson & Johnson to Participate in Citigroup's Global Healthcare Conference
|
| May 16, 2007 |
Cordis To Host Analyst Meeting At EuroPCR 2007
|
| May 11, 2007 |
Southern District Court of New York Rules Patent for ACIPHEX® Enforceable
|
| May 7, 2007 |
Conor Medsystems, LLC Reports COSTAR II Pivotal Drug-Eluting Stent Trial Conclusions
|
| May 4, 2007 |
Ortho-Clinical Diagnostics, Inc. Issues Voluntary, Nationwide Recall for Cardiac Marker
|
| Apr 27, 2007 |
Johnson & Johnson to Participate in Morgan Stanley Conference
|
| Apr 26, 2007 |
Johnson & Johnson Announces Dividend Increase of 10.7%
|
| Apr 19, 2007 |
Johnson & Johnson to Host Annual Meeting of Shareholders
|
| Apr 19, 2007 |
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Breaks Ground on New Facility
|
| Apr 17, 2007 |
Johnson & Johnson Reports 2007 First-Quarter Results: Sales Increase of 15.7% and EPS of $.88 Versus $1.10 a Year Ago; Excluding Special Items, EPS was $1.16, an increase of 17.2% *
|
| Apr 11, 2007 |
Johnson & Johnson to Host Analyst Conference Call on First-Quarter Results
|
| Mar 26, 2007 |
Two-Year Patient Registry Results Support Safety and Efficacy of CYPHER(R) Sirolimus-Eluting Coronary Stent in 'Real World' Uses
|
| Mar 20, 2007 |
Cordis Corporation to Emphasize Commitment to Interventional Cardiology at ACC.07
|
| Mar 13, 2007 |
Johnson & Johnson to Participate in Lehman Brothers Tenth Annual Global Healthcare Conference
|
| Mar 12, 2007 |
Johnson & Johnson Receives Subpoenas
|
| Mar 7, 2007 |
Johnson & Johnson to Participate in the 27th Annual Cowen & Company Health Care Conference
|
| Feb 12, 2007 |
Johnson & Johnson Statement on Voluntary Disclosure
|
| Feb 1, 2007 |
Johnson & Johnson Completes Acquisition of Conor Medsystems, Inc.
|
| Jan 23, 2007 |
Johnson & Johnson Reports Fourth-Quarter and Full-Year 2006 Results
|
| Jan 17, 2007 |
Johnson & Johnson to Review Fourth-Quarter and Full-Year 2006 Financial Results
|
| Dec 20, 2006 |
Johnson & Johnson Completes Acquisition of Pfizer Consumer Healthcare
|
| Dec 12, 2006 |
Johnson & Johnson Acquisition of Pfizer Consumer Healthcare Receives Clearance from U.S. Federal Trade Commission (FTC)
|
| Dec 11, 2006 |
Analysis From Real-World Drug Administration Data Suggests Lower Drug Cost For PROCRIT(R) (Epoetin Alfa) in Outpatient Setting
|
| Nov 27, 2006 |
Winter Sun's Rays Can Be Damaging to Eyes
|
| Nov 16, 2006 |
Johnson & Johnson Announces Definitive Agreement to Acquire Conor Medsystems, Inc.
|
| Oct 24, 2006 |
Cordis Corporation To Study Impact Of Contributing Factors To Stent Thrombosis In Expansion Of 30,000-Stent Patient Registry
|
| Oct 24, 2006 |
U.S. District Court Grants Request for Preliminary Injunction to Ortho-McNeil Neurologics, Inc. for TOPAMAX(R)
|
| Oct 17, 2006 |
Johnson & Johnson Reports 2006 Third-Quarter Results: Sales Increase of 7.9% and EPS of $.94 Versus $.85 a Year Ago; Excluding In-Process Research and Development Charges, EPS Increased 15.3% *
|
| Oct 16, 2006 |
Cordis to Host Analyst Meeting at TCT Conference
|
| Oct 16, 2006 |
U.S. District Court Upholds RISPERDAL(R) Patent
|
| Oct 10, 2006 |
Johnson & Johnson to Host Analyst Conference Call on Third-Quarter Results
|
| Oct 6, 2006 |
Robert J. Darretta to Retire as Vice Chairman and CFO of Johnson & Johnson
|
| Sep 28, 2006 |
As U.S. Population Swells to 300 Million, New Survey Examines The Evolution of Motherhood
|
| Sep 13, 2006 |
Johnson & Johnson to Participate in Merrill Lynch Conference
|
| Sep 12, 2006 |
RNAi Pioneer Craig Mello Named Inaugural Winner of the Dr. Paul Janssen Award for Biomedical Research
|
| Sep 7, 2006 |
Johnson & Johnson to Participate in the Bear Stearns 19th Annual Health Care Conference
|
| Aug 29, 2006 |
Johnson & Johnson to Host Medical Devices & Diagnostics Business Review
|
| Jul 25, 2006 |
VISTAKON to Introduce New 1-DAY ACUVUE(R) MOIST(TM) Brand Contact Lenses In U.S. - A Breakthrough in Comfort
|
| Jul 21, 2006 |
Update on FDA Psychopharmacologic Drugs Advisory Committee Meeting for Sept. 7 on Paliperidone Extended-Release Tablets
|
| Jul 18, 2006 |
Johnson & Johnson Reports 2006 Second-Quarter EPS Increase of 10.5% on Sales Increase of 4.7%
|
| Jul 12, 2006 |
Investigational Drug Paliperidone ER Significantly Delayed Symptom Recurrence In Clinical Study of Patients With Schizophrenia
|
| Jul 12, 2006 |
Johnson & Johnson to Host Analyst Meeting to Discuss Second-Quarter Financial Results; Review Pharmaceuticals Business/Pipeline and the Planned Acquisition of Pfizer Consumer Healthcare
|
| Jul 11, 2006 |
New Survey Reveals Many Contact Lens Wearers Find Their Lenses Uncomfortable, Disruptive When Experiencing Eye-Allergy Symptoms
|
| Jul 6, 2006 |
2006 NBA Champion Alonzo Mourning Raises Awareness About Kidney Disease
|
| Jun 30, 2006 |
Janssen Pharmaceutica Announces Collaboration with Vertex Pharmaceuticals to Develop and Commercialize VX-950 for Treatment of Hepatitis C
|
| Jun 26, 2006 |
Johnson & Johnson to Acquire Pfizer Consumer Healthcare; Combination Creates World's Premier Consumer Health Care Company
|
| Jun 23, 2006 |
American Optometric Association Awards ACUVUE ADVANCE, ACUVUE OASYS Brands With Seal of Acceptance for UV Absorbing Contact Lenses
|
| Jun 8, 2006 |
Johnson & Johnson to Participate in Goldman Sachs Conference
|
| Jun 1, 2006 |
Update On Regulatory Filing Plans for Investigational Compound Trabectedin in Soft Tissue Sarcoma
|
| May 23, 2006 |
Clinical Study of Investigational Drug Paliperidone ER Demonstrated Efficacy and Tolerability in the Treatment of Patients With Schizophrenia
|
| May 16, 2006 |
Physicians Now Have a New Treatment Option for Patients With a Common Vascular Disease Affecting the Legs
|
| May 11, 2006 |
District Court Issues Two Decisions Regarding Patent Litigation Between Cordis Corporation and Boston Scientific
|
| May 11, 2006 |
Johnson & Johnson to Participate in the Banc of America Securities Health Care Conference 2006
|
| May 10, 2006 |
Pharmaceutical Operating Companies of Johnson & Johnson Continue Patient Assistance for Eligible Medicare Beneficiaries
|
| May 9, 2006 |
ETHICON, Inc. Completes Acquisition of Vascular Control Systems, Inc.
|
| May 5, 2006 |
Janssen-Cilag Submits Marketing Authorization Application in Europe for New Treatment for Schizophrenia
|
| Apr 27, 2006 |
Johnson & Johnson to Participate in Morgan Stanley Conference
|
| Apr 27, 2006 |
Johnson & Johnson Announces Dividend Increase of 13.6%
|
| Apr 24, 2006 |
Johnson & Johnson to Host Annual Meeting of Shareholders
|
| Apr 18, 2006 |
Johnson & Johnson Reports 2006 First-Quarter EPS Rose 17.0% on Sales Increase of 1.2%
|
| Apr 11, 2006 |
Johnson & Johnson to Host Analyst Conference Call on First-Quarter Results
|
| Mar 31, 2006 |
Ortho-Clinical Diagnostics Issues a Voluntary Product Recall for VITROS(R) Immunodiagnostic Products Signal Reagent
|
| Mar 28, 2006 |
Johnson & Johnson Presents $100,000 Grant for SF Disaster Preparedness & Neighborhood Emergency Response Training (NERT) Program
|
| Mar 23, 2006 |
Johnson & Johnson Consumer France SAS to Acquire Groupe Vendome SA
|
| Mar 20, 2006 |
Increased Use of Computers, Portable Gadgets Leading to More Visual Fatigue And Discomfort
|
| Mar 8, 2006 |
Johnson & Johnson Announces Stock Repurchase Program
|
| Mar 1, 2006 |
Johnson & Johnson To Participate In The 26th Annual Cowen & Company Health Care Conference
|
| Feb 23, 2006 |
Silver Medalists Belbin & Agosto See Gold With ACUVUE® OASYS Brand
|
| Feb 17, 2006 |
Johnson & Johnson Completes Acquisition of Animas Corporation
|
| Feb 13, 2006 |
Charles Prince of Citigroup Elected to Johnson & Johnson Board of Directors
|
| Feb 1, 2006 |
Johnson & Johnson to Participate in Merrill Lynch Conference
|
| Jan 30, 2006 |
European Commission Approves IONSYS(TM) (Fentanyl HCl Iontophoretic Transdermal System)
|
| Jan 25, 2006 |
Johnson & Johnson Statement Regarding Guidant Corporation
|
| Jan 24, 2006 |
Johnson & Johnson Reports Full-Year and Fourth-Quarter 2005 Results
|
| Jan 19, 2006 |
DePuy Orthopaedics Concludes Acquisition of Hand Innovations LLC
|
| Jan 18, 2006 |
Johnson & Johnson to Review Fourth-Quarter and Full-Year 2005 Financial Results
|
| Jan 17, 2006 |
Johnson & Johnson Statement Regarding Guidant Corporation Acquisition
|
| Jan 13, 2006 |
Guidant Corporation and Johnson & Johnson Announce New Definitive Acquisition Agreement
|
| Jan 11, 2006 |
Guidant Corporation and Johnson & Johnson Announce New Definitive Acquisition Agreement
|
| Jan 8, 2006 |
Johnson & Johnson Reaffirms Commitment to Guidant Acquisition
|
| Jan 3, 2006 |
Scios Submits Interim Report to FDA on NATRECOR®(nesiritide) PROACTION Trial
|
| Dec 28, 2005 |
Johnson & Johnson and Guidant Corporation Proposed Merger Registration Statement Declared Effective
|
| Dec 21, 2005 |
Personal Products Company Completes Acquisition of REMBRANDT(R) Brand From The Gillette Company
|
| Dec 16, 2005 |
Johnson & Johnson Announces Definitive Agreement to Acquire Animas Corporation, an Insulin Delivery Company
|
| Dec 14, 2005 |
Potential New Treatment for Patients with Schizophrenia
|
| Dec 8, 2005 |
Contact Lens Made With New Silicone Hydrogel Material May Help Reduce Most Frequently Reported Lens Problems, Study Shows
|
| Dec 6, 2005 |
Johnson & Johnson Files Form S-4 Registration Statement Regarding Acquisition of Guidant Corporation
|
| Dec 1, 2005 |
ALZA Corporation Modifies U.S. Clinical Development Program for OROS Hydromorphone (AP-77)
|
| Nov 30, 2005 |
New Drug Application Submitted for Potential New Treatment for Schizophrenia
|
| Nov 28, 2005 |
ALZA Corporation Resubmits U.S. New Drug Application for IONSYS(TM) (Fentanyl HCl Patient-Activated Transdermal System)
|
| Nov 22, 2005 |
Johnson & Johnson to Participate in Fifth Annual Merrill Lynch Med Tech Fundamentals Conference
|
| Nov 15, 2005 |
Johnson & Johnson and Guidant Corporation Announce Revised Acquisition Agreement with Net Value of $19 Billion
|
| Nov 10, 2005 |
Study Finds Patients with Moderate to Severe Chronic Kidney Disease Go Undiagnosed
|
| Nov 7, 2005 |
Johnson & Johnson Statement Regarding Guidant Corporation Civil Suit
|
| Nov 3, 2005 |
Johnson & Johnson to Participate in CIBC World Markets Sixteenth Annual Health Care Conference
|
| Nov 2, 2005 |
Johnson & Johnson Receives FTC Clearance of Proposed Acquisition of Guidant Corporation and Provides Update on Transaction in Light of Guidant Recall Events
|
| Oct 26, 2005 |
Tibotec Announces U.S. Expanded Access Program for TMC114
|
| Oct 24, 2005 |
Personal Products Company to Acquire Rembrandt Brand from The Gillette Company
|
| Oct 18, 2005 |
Johnson & Johnson Reports 2005 Third-Quarter EPS Rose 11.5% on Sales Increase of 6.6%
|
| Oct 14, 2005 |
European Authorities Recommend Approval for IONSYS(TM)
|
| Oct 12, 2005 |
Johnson & Johnson to Host Analyst Conference Call on Third-Quarter Results
|
| Sep 28, 2005 |
Cordis Corporation Acquires LuMend, Inc.
|
| Sep 26, 2005 |
Basketball Star Alonzo Mourning Spreads the Word About Kidney Disease
|
| Sep 22, 2005 |
Head-to-Head Study of Treatments for Chemotherapy-Related Anemia Published in The Oncologist
|
| Sep 7, 2005 |
Johnson & Johnson to Participate in the 18th Annual Bear Stearns 2005 Health Care Conference
|
| Sep 2, 2005 |
Johnson & Johnson Advised by Canadian Competition Bureau on Proposed Acquisition of Guidant Corporation
|
| Aug 25, 2005 |
Johnson & Johnson Announces European Commission Clearance of Guidant Acquisition
|
| Aug 11, 2005 |
Newly Published Study Evaluates Extended Dosing Regimens of PROCRIT® (Epoetin alfa) as Maintenance Treatment for Patients with Anemia from Chronic Kidney Disease
|
| Aug 2, 2005 |
Johnson & Johnson Adopts PhRMA Guidelines on Direct-to-Consumer Advertising
|
| Jul 26, 2005 |
Johnson & Johnson Becomes Official Partner of Beijing 2008 Olympic Games, Torino 2006 Olympic Winter Games, USOC and National Olympic Teams
|
| Jul 20, 2005 |
Scios Inc. Receives Subpoena on NATRECOR(R) (Nesiritide)
|
| Jul 19, 2005 |
Scios Inc. Announces Redemption of 5.50% Debentures Due August 2009
|
| Jul 19, 2005 |
Johnson & Johnson Reports 2005 Second-Quarter Sales Increase of 11.1% and EPS of $.89 Versus $.82 a Year Ago; Excluding In-Process Research and Development Charges and Revised Tax Impact of American Jobs Creation Act, EPS Increased 13.4%*
|
| Jul 12, 2005 |
Johnson & Johnson to Host Analyst Conference Call on Second Quarter Results
|
| Jul 1, 2005 |
Cordis to Ask Judge to Overturn Patent Verdict
|
| Jun 30, 2005 |
Cordis Endovascular Launches PALMAZ(R) BLUE(TM) Transhepatic Biliary Cobalt Chromium Stent in U.S.
|
| Jun 30, 2005 |
Johnson & Johnson Completes Acquisition of Peninsula Pharmaceuticals, Inc.
|
| Jun 21, 2005 |
Jury Finds Cordis Patents Infringed by Boston Scientific Stents
|
| Jun 17, 2005 |
Johnson & Johnson Statement Regarding Guidant Transaction
|
| Jun 9, 2005 |
Cordis Corporation to Appeal Court Ruling
|
| Jun 3, 2005 |
Johnson & Johnson Completes Acquisition of CLOSURE Medical Corporation
|
| Jun 2, 2005 |
New Online Greeting Card Promotes Awareness of Chronic Kidney Disease During Hispanic Health Month
|
| Jun 2, 2005 |
World-Renowned Chef and Cancer Survivor Biba Caggiano Visits Long Island Hospitals to Help Cancer Patients Find Strength for Living
|
| May 24, 2005 |
Johnson & Johnson Statement Regarding Guidant Transaction
|
| May 19, 2005 |
Johnson & Johnson to Host Pharmaceutical Research and Development Review
|
| May 18, 2005 |
CYPHER(R) Sirolimus-eluting Coronary Stent Clinical Data to Be Featured at 2005 EuroPCR
|
| May 17, 2005 |
Online Greeting Card Series Honors Women Affected by Chronic Kidney Disease
|
| May 15, 2005 |
Head-to-Head Study of Treatments for Chemotherapy-Related Anemia Found Patients Treated With Procrit(R) Demonstrated Greater Increase in Red Blood Cell Levels, Required Less Transfused Blood
|
| Apr 29, 2005 |
Johnson & Johnson to Participate in Morgan Stanley Conference
|
| Apr 29, 2005 |
World-Renowned Chef and Cancer Survivor Biba Caggiano Shares Ingredients for Helping Cancer Patients Find Strength for Living
|
| Apr 28, 2005 |
Johnson & Johnson Announces Dividend Increase of 15.8%
|
| Apr 27, 2005 |
New ACUVUE(R) ADVANCE(TM) Brand Contact Lenses for ASTIGMATISM Offer Consistent All-Day Vision, Comfort in The 'Blink Of An Eye'
|
| Apr 26, 2005 |
|
| Apr 22, 2005 |
Johnson & Johnson Proposed Acquisition of Guidant Corporation Enters Second Phase Review by European Commission
|
| Apr 21, 2005 |
Johnson & Johnson to Host Annual Meeting of Shareholders
|
| Apr 20, 2005 |
CYPHER(R) Sirolimus-Eluting Coronary Stent Receives FDA Approval for MRI Scans Immediately Following Implantation
|
| Apr 19, 2005 |
Johnson & Johnson - The World's Most Broadly Based Health Care Company Reports 2005 First-Quarter EPS Rose 16.9% on Sales Increase of 11.0%
|
| Apr 19, 2005 |
Johnson & Johnson Announces Agreement to Acquire Peninsula Pharmaceuticals, Inc.
|
| Apr 13, 2005 |
Johnson & Johnson to Host Analyst Conference Call on First Quarter Results
|
| Apr 5, 2005 |
U.S. Pharmaceutical and Biotechnology Companies of Johnson & Johnson Participate in Partnership for Prescription Assistance
|
| Apr 4, 2005 |
Johnson & Johnson Completes Acquisition of TransForm Pharmaceuticals, Inc.
|
| Mar 30, 2005 |
DePuy Orthopaedics, Inc. Receives Subpoena
|
| Mar 24, 2005 |
Johnson & Johnson and Guidant Corporation Proposed Merger Registration Declared Effective
|
| Mar 14, 2005 |
Michael M.E. Johns, M.D. of Emory University Nominated for Election to the Johnson & Johnson Board of Directors
|
| Mar 9, 2005 |
Johnson & Johnson to Acquire TransForm Pharmaceuticals
|
| Mar 6, 2005 |
Arts II Clinical Study Shows Promising Results for the Cypher(R) Sirolimus-Eluting Coronary Stent In Patients With Multi-Vessel Disease
|
| Mar 6, 2005 |
REALITY Trial Data Suggest Drug-Eluting Stents Differ Significantly in Rate of Blood Clot Formation-Stent Thrombosis
|
| Mar 4, 2005 |
Johnson & Johnson and CLOSURE Medical Corporation Announce Acquisition Agreement
|
| Mar 4, 2005 |
Multimedia Available: Basketball Star Alonzo Mourning Reaches Out to Fellow Kidney Disease Patients with New Series of Online Greeting Cards
|
| Mar 1, 2005 |
Cordis to Host Analyst Meeting to Review REALITY Trial Results
|
| Feb 28, 2005 |
Multimedia Available: KidneyResource.com: A New Internet Gateway to Science-Based Information About Chronic Kidney Disease
|
| Feb 24, 2005 |
CYPHER(R) Sirolimus-Eluting Coronary Stent to Be Featured in Late-Breaking Clinical Trial Presentations at 2005 American College of Cardiology Scientific Session
|
| Feb 24, 2005 |
CYPHER(R) Sirolimus-Eluting Coronary Stent to Be Featured in Late-Breaking Clinical Trial Presentations at 2005 American College of Cardiology Scientific
|
| Feb 18, 2005 |
Johnson & Johnson and Guidant Corporation Will Respond to Federal Trade Commission's Request For Information
|
| Feb 14, 2005 |
Stories of Survival and Hope Mark the One Million Patient Milestone For the CYPHER(R) Sirolimus-eluting Coronary Stent
|
| Feb 3, 2005 |
Johnson & Johnson to Participate in Merrill Lynch Conference
|
| Jan 25, 2005 |
Johnson & Johnson - The World's Most Broadly Based Health Care Company 2004 Fourth-Quarter Sales Increased 13.3% Tax Impact of American Jobs Creation Act Reduced Fourth-Quarter Earnings 2004 Full Year EPS Rose 18.3% on Sales Increase of 13.1%
|
| Jan 24, 2005 |
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Completes Submission of Tipifarnib NDA to FDA Continuous Marketing Application Pilot-1 Program
|
| Jan 21, 2005 |
Health Authorities Reviewing Safety Data from Investigational Study Involving REMINYL(R) (galantamine hydrobromide)
|
| Jan 18, 2005 |
Johnson & Johnson To Review Fourth-Quarter Results
|
| Jan 12, 2005 |
Christine A. Poon Appointed a Vice Chairman of Johnson & Johnson
|